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ABSTRACT
ENHANCING THE IDENTIFICATION OF RHEUMATOID ARTHRITIS-ASSOCIATED
LUNG DISEASE
Bryant R. England, M.D., Ph.D.
University of Nebraska, 2019
Supervisor: Ted R. Mikuls, M.D., M.S.P.H
Rheumatoid arthritis (RA) is a systemic autoimmune disease that predisposes afflicted
individuals to reduced quality of life, physical disability, and premature mortality. While
joint involvement is the primary manifestation of RA, extra-articular features including
lung disease are responsible for a significant portion of the excess mortality. In this
dissertation I demonstrate the contribution of chronic lung diseases to premature
mortality in RA, contrasting with the more widely recognized comorbidity in RA of
cardiovascular disease. Then, I establish that a novel serum biomarker, antimalondialdehyde-acetaldehyde adduct (MAA) antibody, is associated with the presence
of interstitial lung disease (ILD) in RA subjects. Further implicating its role in the
pathogenesis of RA-ILD, I will demonstrate the presence of MAA as well as the colocalization of MAA with RA autoantigens and immune effectors cells in the lungs of RAILD subjects. Finally, I describe how biomedical informatics algorithms that incorporate
multiple ILD diagnosis codes, provider specialty, and diagnostic testing can accurately
classify ILD status in RA subjects. Together, these studies advance our ability to identify
RA-associated lung diseases across the spectrum of clinical and translational research.
These results will pave the way for future clinical and translational research studies to
compose biomarker panels that aid in the screening of RA subjects for lung disease,
identify pathways that could be targeted for novel therapeutics in RA-ILD, and facilitate
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the completion of comparative effectiveness and outcomes research studies using realworld data.
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CHAPTER 1: INTRODUCTION
1.1

Rheumatoid Arthritis
Rheumatoid arthritis (RA) is a chronic, autoimmune disease that affects between

0.5 and 1.0% of the United States population.1 Women are most commonly afflicted with
RA, with the highest incidence rates occurring in those in the 6th to 7th decade of life.2
The typical presentation of RA is characterized by swelling, pain, and stiffness in the
small joints of the hands and feet, but frequently involves additional medium to large
joints over time.3 If left untreated, the articular manifestations of RA can lead to bone
erosions, joint deformities, and functional impairment. While joint symptoms often herald
the onset of RA and are the primary target of treatment, RA is a systemic disease with
numerous extra-articular manifestations. These diverse extra-articular manifestations
include cardiovascular disease, pulmonary disease, ophthalmic disease, osteoporosis,
and subcutaneous nodules, among others.4 Although RA is most common among
females, extra-articular manifestations have a predilection to affect males.5
Establishing the diagnosis of RA has been facilitated by the identification of
serum biomarkers closely associated with RA. Rheumatoid factor (RF) is an antibody
targeting the Fc portion of an IgG that is present in approximately 70% of RA patients.6
Generation of these antibodies is not unique to RA, with RF also being detected in other
autoimmune or infectious diseases.7 Anti-citrullinated protein antibodies (ACPAs) target
citrullinated peptides formed through a process of citrullination, when arginine is
converted to citrulline by peptidylarginine deiminase enzymes.8 Similarly to RF, ACPAs
are detected in approximately 70% of RA patients.6 However, the specificity of ACPAs
for RA is greater than RF, reported to be >95% in a large meta-analysis.6 Several other
novel autoantibodies are currently being investigated in RA. These include antibodies
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targeting malondialdehyde-acetaldehyde (MAA) adducts, a product of oxidative
stress,9,10 as well as anti-carbamylated protein antibodies11 and antibodies against
peptidylarginine deiminases.12
While the pathophysiology of RA is not fully understood, both genetic
predisposition and environmental factors drive RA risk. HLA-DRB1 alleles encoding a
five amino acid sequence at position 70-74 of the HLA-DRβ chain, termed the shared
epitope, carry among the highest genetic risk for developing RA.13 More recently, HLADRB1 haplotypes that include the amino acid valine at position 11 have also been
associated with RA incidence and severity.14,15 Outside of the human leukocyte antigen
region, PTPN22 single nucleotide polymorphisms carry heightened RA risk.16 While
various environmental factors have been studied as risk factors for RA, tobacco smoke
is the strongest environmental risk factor identified to date, an association more closely
linked to seropositive RA.17,18 Moreover, a strong gene-environment interaction between
shared epitope alleles and tobacco smoke has been observed, with seropositive RA risk
21-fold higher among smokers with shared epitope alleles.19 Recent work harnessing
longitudinal biorepositories has allowed investigators to discover the “pre-clinical” period
of RA when autoantibodies are detected years in advance of clinical symptoms.20 Proinflammatory cytokine production may signal the imminent transition from “pre-clinical” to
“clinical” RA.21
As a result of the articular and extra-articular manifestations of RA, affected
individuals are at risk for poor long-term outcomes. Individuals with RA have reduced
quality of life,22 physical impairment,23 work disruption,24 and may require joint
replacement surgery.25 Furthermore, individuals with RA have higher mortality rates than
the general population.26,27 Many of these affected health domains are exacerbated by
the increased comorbidity burden present in RA patients. Common comorbid conditions
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afflicting RA patients include pulmonary disease, cardiovascular diseases, ophthalmic
diseases, osteoporosis and fractures, mental health disorders, and chronic pain
disorders, including fibromyalgia, among others.28,29 Because comorbidities may be a
manifestation of RA, a consequence of RA or its treatment, or related to a common
external risk factor,28 differentiating extra-articular manifestations of RA from an RArelated comorbidity is inherently complex.
To optimally prevent the aforementioned short- and long-term complications, RA
must be aggressively managed using disease-modifying anti-rheumatic drugs
(DMARDs), medications that have demonstrated the ability to slow articular disease
progression. Current American College of Rheumatology (ACR) and European League
Against Rheumatism guidelines recommend the early initiation of DMARDs after RA
diagnosis with a treatment goal of achieving and maintaining low disease activity or
remission.30,31 RA disease activity is typically assessed by composite disease activity
measures that incorporate patient and/or provider assessments such as swollen and
tender joint counts, and laboratory tests.32,33 Methotrexate is currently the cornerstone
therapy in RA, but many RA patients will not reach treatment goals on methotrexate
monotherapy.34 Escalation to combination DMARDs (e.g. triple therapy – the
combination of methotrexate, hydroxychloroquine, and sulfasalazine),35 biologic
DMARDs (bDMARDs), or targeted-synthetic DMARDs typically occurs when treatment
goals are not met with methotrexate alone.30,31 As a result of early aggressive treatment,
treating-to-a-target, and an expanding repertoire of treatment options, more RA patients
are meeting treatment goals,36 fewer joint replacement surgeries are occurring,37 and
physical function among RA populations is improving.38 However, these improvements
have not necessarily been accompanied by improvements in survival, where results are
conflicting and several studies in the modern treatment era continue to observe higher
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mortality in RA patients than the general population.39 Analyses of RA patients
diagnosed between 1980 and 2007 in Olmstead County, Minnesota suggest
improvement in cardiovascular mortality, but not other causes of death.40 Recent large
cohort studies in men and women with RA, including work by our group, highlight
respiratory disease as a major driver of premature mortality in RA.26,27 The reasons
underlying this lag in improvement of non-cardiovascular deaths are not well elucidated,
but widespread efforts to identify and target cardiovascular disease in RA have been
implemented over the prior two decades.41 In contrast, there have been fewer attempts
to identify and target other causes of mortality, including lung disease.

1.2

Lung Disease in Rheumatoid Arthritis
The three initial cases of pulmonary involvement secondary to RA were recorded

in 1948 by Ellman and Ball in the British Medical Journal.42 These cases, 2 of which
proved fatal, described findings consistent with interstitial lung disease (ILD). In 1953,
Anthony Caplan described 51 cases of radiologic abnormalities in the lungs of coal
miners with RA.43 In addition to fibrosis that was present in 90% of cases, a unique
presentation of well-defined multifocal opacities was noted that later became termed
Caplan syndrome. These landmark reports inspired widespread efforts to characterize
and evaluate pulmonary manifestations accompanying RA and were essential for
recognizing the systemic nature of RA. Today, a wide array of pulmonary manifestations
are recognized to complicate the natural course of RA. These include pulmonary
nodules, pleural effusions/serositis, ILD, bronchiectasis, and bronchiolitis.44 Common
chronic lung diseases in the general population, such as chronic obstructive pulmonary
disease (COPD), also appear to be overrepresented among RA subjects, even after
accounting for tobacco use.45,46
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In addition to being associated with established RA, the lungs appear to be a site
where RA autoantibody responses are generated and lung disease may be the initial
manifestation of RA.47,48 RA autoantibodies have been detected in individuals with
chronic lung disease in the absence of articular manifestations,49 and cigarette smoking,
the strongest environmental risk factor for RA, induces citrullination in the lungs.50
Further suggesting a potential pathogenic link between the lungs and joints are the
presence of airway abnormalities and sputum RA autoantibody expression in individuals
at high risk for RA,51,52 enrichment of ACPAs in the sputum and bronchoalveolar fluid
from patients with RA,52-54 and identification of shared citrullinated peptides in the lung
and joint tissue from patients with RA.55 The aforementioned findings and a growing
understanding of the links between mucosal and systemic autoimmunity have sparked
great interest in whether the lungs may be an originating site of RA.56
Clinical and translational research on lung disease in RA has largely focused on
ILD, which clinically affects between 5-15% of RA patients and up to three-fold more
subclinically.48,57 The pathogenesis of RA-ILD is poorly understood, but believed to be a
result of genetic predisposition and environmental exposures (e.g., tobacco use) that
drive autoimmunity, pro-inflammatory responses, oxidative stress, fibrosis, and
remodeling of the extracellular matrix.44 These processes result in inflammation and
fibrosis of the lungs, which cause symptoms like shortness of breath, dyspnea on
exertion, and non-productive cough.58 Risk factors for developing RA-ILD include older
age, male sex, tobacco use, other extra-articular features of RA, and RA disease
severity.48,57,59,60 There are unique patterns of RA-ILD which historically were determined
by surgical lung biopsy but more recently are determined by high-resolution computed
tomography (CT). The most common histopathologic pattern in RA-ILD is usual
interstitial pneumonia,48,61 as in idiopathic pulmonary fibrosis (IPF). The genetic basis for
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RA-ILD also appears to be shared with IPF. A MUC5B promoter variant previously linked
to IPF was recently identified to be associated with RA-ILD, particularly the usual
interstitial pneumonia pattern.62 The prognosis is poor in RA-ILD, with a median survival
after diagnosis of RA-ILD reported to be less than 3 years.47,57 Only a marginally better
prognosis has been suggested by other studies.63,64
Further highlighting the impact of lung diseases on long-term outcomes was a
prior study of mortality we conducted among male U.S. Veterans with RA. We observed
a significantly higher risk of death among the RA subjects compared to age- and sexmatched rates.26 Moreover, respiratory-related mortality was the most overrepresented
cause of death among RA subjects with rates nearly 3-fold higher than age- and sexmatched general population rates (Figure 1). Among these respiratory deaths, COPD
was the most frequent respiratory cause of death. Sparks et al. similarly found
respiratory diseases to be the most overrepresented cause of death in a 36-year study
of nurses with RA.27 In concordance with our findings, COPD was the most frequent
respiratory cause of death in their study. Together, these studies demonstrate the longterm consequences of chronic lung disease and the need to study the impact of lung
diseases besides RA-ILD on long-term outcomes.
A hypothesized factor contributing to poor long-term outcomes in RA-associated
lung disease is the delayed identification of lung diseases, particularly for RA-ILD.
Current methods to identify RA-ILD include chest radiography, high-resolution CT, and
pulmonary function tests (PFTs). Typically, testing with these modalities is prompted by
the development of respiratory symptoms including cough, shortness of breath, or
dyspnea on exertion. Relying on the development of clinical symptoms to prompt testing
inherently results in late detection, with up to 30% of RA patients having subclinical ILD
on CT.65 Ideally, a screening method to identify RA patients at highest risk for lung

7

diseases could be used to tailor screening approaches. But accounting for the few
established risk factors for RA-ILD,48,57,59,66-68 is neither sensitive nor specific enough to
use in the clinical setting. Better methods to identify individuals with, or at risk for, RAILD would allow for studying and implementing targeted therapies earlier in the disease
course before irreversible fibrosis is established.
Serum biomarkers have the potential to serve this role as part of RA-ILD
screening protocols. Candidate biomarkers identified in RA-ILD to date have included
Krebs von den Lungen-6,64,69 ACPA,66 anti-citrullinated heat shock protein-90 (anti-cit
HSP90 antibody),70 matrix metalloproteinase-7 (MMP-7),71,72 interferon-y inducible
protein-10 (IP-10),71 pulmonary and activation-regulated chemokine (PARC),72 and
surfactant protein-D (SP-D).72 Investigation of these RA-ILD serum biomarkers has been
limited by small sample sizes, failing to account for predictive clinical factors or
appropriate disease controls, and minimal (or absent) external validation. The
identification of serum biomarkers to enhance the detection of RA-ILD remains a critical
knowledge gap.73
Also responsible for the poor long-term outcomes in RA-associated lung disease
is uncertainty regarding optimal treatment approaches. There are no completed
controlled trials, nor are there clinical practice guidelines, to inform the management of
RA-associated lung disease. This is again most troublesome in RA-ILD, where there is
concern that the use of many RA therapies may result in acute episodes of pneumonitis
or even progression of underlying ILD. Essentially all DMARDs approved for the
treatment of RA have been reported to be associated with drug-induced pneumonitis,
which can greatly complicate the diagnosis and/or management of RA-related
pulmonary manifestations.74-76 In the absence of controlled trial data, providers rely on
pharmacoepidemiologic evaluations of drug effectiveness and safety through

8

comparative effectiveness and outcomes research. However, comparative effectiveness
studies in RA-ILD using large observational datasets have been limited by the lack of
validated approaches to identify RA-ILD patients.77-79 This is in contrast to RA, and other
rheumatic diseases, where there has been substantial research on the validity of
administrative based algorithms to build disease cohorts.80-83 The development of
validated algorithms for identifying RA-ILD would allow for comparative effectiveness
and outcomes research with large real-world datasets that could immediately inform and
improve RA-ILD management.
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Figure 1. Standardized mortality ratios for cause-specific mortality by enrollment
disease activity in men with RA

Age-adjusted standardized mortality ratios and 95% confidence intervals (CIs) for allcause, cardiovascular, cancer, and respiratory-related mortality among men with RA
using U.S. life tables from the Centers for Disease Prevention and Control. Overall
mortality rates and mortality rates stratified by RA disease activity state (remission, low,
moderate, and high) are shown. Reprinted with permission from: England BR et al.
Cause-Specific Mortality in Male US Veterans with Rheumatoid Arthritis. Arthritis Care
Res (Hoboken), 2016;68(1):36-45.
Abbreviations: CI, confidence interval; DAS-28, 28-joint Disease Activity Score; SMR,
standardized mortality ratio
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1.3

Objectives
The overall objective of this dissertation is to identify means to enhance the

identification and investigation of RA-associated lung disease.
In Chapter 2, I use freely available comorbidity classification software to assess
the impact of chronic lung diseases, including RA-ILD and other chronic lung diseases,
on survival in RA. Additionally, I contrast the risk of death in RA for individuals with
chronic lung diseases compared to those with cardiovascular disease, a widely
recognized determinant of poor long-term outcomes in RA.
In Chapter 3, I evaluate biological methods to identify RA-ILD by testing whether
a novel serum autoantibody, anti-MAA, is associated with the presence of ILD among a
large cohort of RA subjects. Furthermore, I investigate whether MAA modified proteins
are present in lung tissues from RA-ILD subjects and whether these modified proteins
colocalize with other recognized RA-related autoantigens (namely citrullinated proteins)
and/or biologically relevant immune effector cells.
In Chapter 4, I leverage biomedical informatics approaches to derive
administrative data algorithms that can accurately identify RA-ILD in large, real-world
datasets.
Finally, in Chapter 5, I discuss how the findings from this dissertation improve our
ability to identify RA-associated lung disease and pave the way for future high-impact
clinical and translational research in RA-associated lung disease to improve the existing
poor long-term outcomes for this high-risk patient population.
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CHAPTER 2: IMPORTANCE OF LUNG DISEASE
2.1

Background
Several chronic lung diseases have been described in RA including ILD,

obstructive lung diseases (COPD, bronchiectasis, bronchiolitis), pulmonary nodules,
medication toxicities, and pleural diseases. Perhaps the most concerning of these
pulmonary manifestations is ILD, which is clinically apparent in 5-15% of RA patients
and carries a poor long-term prognosis.44,47,57,84 In our prior work, we demonstrated that
respiratory-related deaths were the most over-represented cause of death in men with
RA 26 and similar findings were reported in women with RA in the Nurses’ Health
Study.27 In both studies, COPD, rather than ILD, was the leading cause of respiratoryrelated death in RA. Despite their frequency, the prognostic importance of lung diseases
in RA beyond ILD is not well established. In a population-based incident RA cohort
study, obstructive lung disease (defined as an obstructive defect on spirometry and a
physician diagnosis of airway or parenchymal lung disease) was associated with a 2-fold
higher risk of mortality.46 Bronchiectasis and bronchiolitis have also been reported to
increase the risk of mortality in RA patients in a few small studies.64,85,86
In addition to RA itself, several DMARDs have been implicated in chronic lung
diseases (e.g. drug-induced pneumonitis).87-90 Moreover, increased adverse events were
reported in COPD patients receiving abatacept in a randomized controlled trial.91
Because of the potential for pulmonary toxicity with these agents, there is significant
concern regarding optimal DMARD selection in patients with chronic lung disease,
evidenced by epidemiologic channeling to leflunomide (away from methotrexate) in RA
patients with ILD.78 The long-term safety and best practices for the use of DMARDs in
RA patients with chronic lung disease remains an important and unanswered question.
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Our objective was to evaluate the risk of death among RA patients with chronic
lung disease, including chronic lung diseases other than ILD. To illustrate its importance
on RA outcomes, we contrasted this risk with cardiovascular disease, another
overrepresented comorbid condition in RA patients that is well-established as a
determinant of poor long-term outcomes.26,41,92 Additionally, we investigated whether
select DMARD use in RA patients with chronic lung disease was associated with
differential impact on survival.

2.2

Methods

Participants
We utilized the Veterans Affairs Rheumatoid Arthritis (VARA) Registry, a
multicenter longitudinal observational cohort study of U.S. Veterans with RA fulfilling the
1987 ACR classification criteria.93 The VARA Registry, initiated in 2003, has been well
described previously.94 Subjects were followed from the time of enrollment until death or
censoring at the end of available vital status data (December 31, 2013). All subjects
provided written informed consent before enrollment, and each site received institutional
review board approval. This study was approved by the VARA Scientific Ethics Advisory
Committee.
Chronic lung disease assessment
Recognizing that chronic lung diseases are often characterized by an insidious
onset of pulmonary symptoms leading to diagnosis, we assessed prevalent chronic lung
disease by using outpatient diagnostic codes within the VA Corporate Data Warehouse
collected over a 2-year period, 12 months prior to and 12 months following enrollment.
Diagnostic codes were categorized using the Healthcare Cost and Utilization Project
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Clinical Classification Software (HCUP-CCS, https://www.hcup-us.ahrq.gov/). HCUPCCS is a freely available software tool developed by the Agency for Healthcare
Research and Quality that categorizes International Classification of Diseases (ICD), 9th
Revision, Clinical Modification codes into 295 distinct categories. Chronic lung disease
categories included were 127: chronic obstructive pulmonary disease and
bronchiectasis, 128: asthma, 132: lung disease due to external agents; and 133: other
lower respiratory disease. Respiratory codes representing acute lung conditions were
not included (122: pneumonia; 123: influenza; 125: acute bronchitis; 126: other upper
respiratory infections; 129: aspiration pneumonitis, food/vomitus; 130: pleurisy,
pneumothorax, pulmonary collapse, 131: respiratory failure, insufficiency, arrest; 134:
other upper respiratory disease). Diagnostic codes (ICD-9-CM) corresponding to these
HCUP-CCS categories are shown in Appendix A. Chronic lung disease categories were
not mutually exclusive (i.e., patients could have multiple chronic lung diseases). To
enhance the specificity of disease classification, we required at least two HCUP-CCS
codes within this 24-month window and at least one of these codes to have occurred
prior to VARA enrollment. Cardiovascular disease was assessed in the same manner,
using HCUP-CCS categories 96-97, 100-101, 105-110, and 112-114 (Appendix B).
Recognizing that ICD-9-CM codes commonly used for ILD are included within a HCUPCCS category that also contains non-ILD codes (Appendix C), we used diagnostic
codes specific to ILD (ICD-9-CM: 495, 515-517, 714.81) entered into the registry at
enrollment by treating rheumatologists. An overall measure of comorbidity burden was
assessed using the Rheumatic Disease Comorbidity Index.95
Clinical variables and vital status
In conjunction with routine rheumatology care, ACR core measures were
collected by the treating rheumatologists, including erythrocyte sedimentation rate
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(mm/hour), 28-joint swollen joint count, 28-joint tender joint count, patient and provider
global assessment (0-100mm visual analogue scale), Multidimensional HealthAssessment Questionnaire (MDHAQ) 96 as well as calculation of the Disease Activity
Score in 28 joints (DAS28).97 DMARDs, both biologic and non-biologic, and prednisone
use were similarly collected within the registry. Additional variables collected at
enrollment were sex, smoking status (current, former, never), education level, and selfreported race. HLA-DRB1 shared epitope alleles, C-reactive protein, anti-cyclic
citrullinated peptide (anti-CCP, U/ml) antibody, and RF (IU/ml) were measured using
banked serum and genomic DNA collected at enrollment, as previously described.98,99
Vital status was determined by linkage with the National Death Index (Center of
Excellence for Suicide Prevention, Joint Department of VA and Department of Defense
Suicide Data Repository; http://vaww.virec.research.va.gov/Mortality/Overview.htm;
extract through 2013).26
Statistical analysis
Baseline characteristics were compared between subjects with and without
chronic lung disease at the time of enrollment using chi-square and independent t-tests.
Multivariable Cox proportional hazards models were used to assess the association of
chronic lung disease with all-cause mortality. Covariates included in the Cox models
were age, sex, race, smoking status, MDHAQ, DAS28, baseline DMARDs, and baseline
prednisone use. MDHAQ and DAS28 varied over time, while all other variables were
fixed at enrollment values. To compare mortality risk between chronic lung disease and
cardiovascular disease, a combined categorization was created: neither comorbidity
(referent), chronic lung disease alone, cardiovascular disease alone, or both
comorbidities occurring together.
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Associations of DMARDs with mortality in RA subjects with chronic lung disease
was determined in stratified analyses (all patients, patients with chronic lung disease,
and patients without lung disease) and interaction terms were tested using multivariable
Cox regression models adjusting for age, sex, race, smoking status, MDHAQ, DAS28,
and baseline prednisone use and clustered by enrollment site. DMARDs were modeled
as time-varying and baseline use separately. Because tumor necrosis factor inhibitors
(TNFi) comprised 95% of biologic DMARD use at baseline, all biologic DMARDs were
modeled together. In sensitivity analyses, we assessed DMARDs using propensity score
adjustment. We calculated propensity scores for receiving methotrexate, leflunomide,
hydroxychloroquine, sulfasalazine, azathioprine, or biologic DMARDs at baseline using
age, sex, race, education level, smoking status, chronic lung disease, Rheumatic
Disease Comorbidity Index score, RA disease duration, anti-CCP antibody positivity,
MDHAQ, DAS28, and prednisone use as predictors in logistic regression models. The
resulting propensity scores (both as continuous values and propensity score quintiles)
were entered as a covariate into Cox models with the DMARD of interest. Proportional
hazards assumptions were tested in Cox models by Schoenfeld residuals, which were
not significant. A P value <0.05 was considered significant in all analyses, which were
completed using Stata v15 (StataCorp, College Station, TX).

2.3

Results

Baseline characteristics
Baseline characteristics of the study population (N = 2,053) stratified by chronic
lung disease status are shown in Table 1. Those with chronic lung disease were older (P
< 0.001), male predominant (P = 0.005), less likely to have a high-school education (P =
0.004), more likely to be current or former smokers (P < 0.001), and had higher
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comorbidity scores (P < 0.001). Anti-CCP antibody concentrations were higher in those
with chronic lung disease (mean 286 vs. 230 U/mL, P = 0.007), while frequency of antiCCP and RF positivity and RF concentration did not differ between those with and
without chronic lung disease. Similarly, race, disease duration, subcutaneous nodules,
and shared epitope positivity did not differ by chronic lung disease status.
Frequency of chronic lung disease
Using HCUP-CCS categories, 27% of participants (n = 554) had chronic lung
disease with other lower respiratory disease being the most common (16.1%) followed
by COPD/bronchiectasis (14.7%) (Table 2). Using physician entered diagnostic codes,
the prevalence of COPD (18.1%) was similar while ILD was recorded in 5.2% of
patients.
Chronic lung disease and survival
During a total observation period of 6,682 patient-years, there were 341 deaths
with 139 of these occurring in patients with chronic lung disease (81.6 per 1,000 personyears, 95% confidence interval [CI] 69.1-96.0) and 202 occurring in patients without lung
disease (40.6 per 1,000 person-years, 95% CI 35.4-46.6). Deaths among those with
chronic lung disease occurred on average 1.3 years earlier compared to those without
(mean age at death of 73.3 ± 9.4 vs. 74.6 ± 9.4 years). Respiratory-related deaths
accounted for 22.3% of deaths among those with chronic lung disease, but only for 9.9%
among those without chronic lung disease. Chronic lung disease (per HCUP-CCS
codes) was associated with a significantly greater mortality risk in all models (Table 3).
In fully adjusted models, chronic lung disease was associated with a 51% increased risk
of mortality (hazard ratio [HR] 1.51, 95% CI 1.26-1.81). Except for asthma, each
individual HCUP-CCS chronic lung disease category was associated with a greater
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mortality risk (HRs: COPD/bronchiectasis 1.61, 95% CI 1.39-1.86; other lower
respiratory 1.32, 95% CI 1.27-1.36). Using physician entered diagnostic codes from the
registry, COPD was associated with a 1.48-fold higher mortality risk (95% CI 1.16- 1.90)
and ILD was associated with a 1.90-fold higher mortality risk (95% CI 1.23-2.96).
We then contrasted the mortality risk between chronic lung disease and
cardiovascular disease using a combined lung and cardiovascular disease classification.
Using HCUP-CCS codes, 55.6% of participants had neither lung nor cardiovascular
disease comorbidity, 16.5% of participants had only chronic lung disease, 17.3% had
only cardiovascular disease, and 10.6% had both comorbidities. Both chronic lung
disease and cardiovascular disease were associated with a similar increased risk of
mortality alone compared to individuals free of both conditions (Figure 2; cardiovascular
HR 1.62, 95% CI 1.33-1.94; chronic lung HR 1.46, 95% CI 1.03-2.06). Those
simultaneously afflicted with both chronic lung disease and cardiovascular disease had
numerically higher mortality risk than those with lung or cardiovascular comorbidity alone
(HR 2.28, 95% CI 1.80-2.89). In sub-analyses, COPD by both HCUP-CCS (HR 1.76,
95% CI 1.33-2.32) and physician entered diagnostic codes (1.61, 95% CI 1.28-2.02)
were associated with a similar risk of death as comorbid cardiovascular disease (Table
4). Other lower respiratory comorbidities identified by HCUP-CCS had a numerically
lower risk of death than comorbid cardiovascular disease (other lower respiratory HR
1.13, 95% CI 0.85-1.51; cardiovascular HR 1.56, 95% CI 1.35-1.79) while ILD by
physician entered codes had a numerically higher risk of death (ILD HR 2.18, 95% CI
1.08-4.41; cardiovascular HR 1.73, 95% CI 1.58-1.90). The presence of both lung
disease and cardiovascular disease was associated with the highest risk of death across
all sub-analyses.
DMARDs and mortality risk
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While individual DMARDs demonstrated associations with mortality in general,
no DMARDs (baseline or time-varying use) were associated with an increased risk of
mortality in RA patients with chronic lung disease (Table 5). Furthermore, there was no
evidence of differential risk of mortality with baseline or time-varying methotrexate or
bDMARD use in those with/without chronic lung disease (all P values for interaction ≥
0.15). There was, however, evidence of a significant interaction between
hydroxychloroquine use and chronic lung disease (P ≤ 0.04). In stratified analyses,
hydroxychloroquine use was associated with a numerically more protective association
with mortality in those with chronic lung disease compared to RA subjects without lung
disease; however, associations were not statistically significant within each subgroup.
Sub-analyses stratified by individual lung diseases (HCUP-CCS COPD/bronchiectasis,
other lower respiratory disease; physician entered codes for COPD and ILD) were
consistent with overall lung disease analyses (data not shown). In sensitivity analyses
incorporating propensity scores for baseline medication use, most DMARDs were again
not associated with an increased risk of mortality in those with chronic lung disease,
except for baseline sulfasalazine use (continuous: HR 1.73, 95% CI 1.03-2.91; quintiles:
HR 1.67, 95% CI 1.04-2.69; Table 6).
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Table 1. Baseline characteristics of RA cohort by chronic lung disease status
Variable
Demographics and comorbidities
Age, years
Male sex, %
White, %
High-school education, %
Smoking status, %
Current
Former
Never
Body mass index, kg/m2
RDCI score
RA disease status
RA duration, years
Shared epitope positive, %
Anti-CCP positive, %
Anti-CCP, U/mL
RF positive, %
RF, IU/mL
Nodules, %
MD-HAQ, 0-3
ESR, mm/Hr
C-reactive protein, mg/dL
DAS28
Medications
Methotrexate, %
Leflunomide, %
Hydroxychloroquine, %
Sulfasalazine, %
Biologic DMARD, %
Prednisone, %

Lung Disease
(n=554)

No Lung
Disease
(n=1499)

65.7 (9.9)
93.1
79.0
83.3

62.7 (11.2)
89.2
76.0
88.1

27.9
58.4
13.7
28.5 (5.6)
3.9 (1.2)

25.9
50.5
23.6
28.4 (5.6)
1.7 (1.3)

11.5 (11.5)
72.3
79.3
286 (439)
80.5
370 (719)
31.9
1.0 (0.6)
31.7 (1.2)
1.4 (2.1)
4.1 (1.5)

11.8 (11.4)
71.7
77.0
230 (389)
79.4
328 (707)
29.5
0.9 (0.6)
24.6 (0.6)
1.1 (1.9)
3.9 (1.6)

0.60
0.82
0.25
0.007
0.59
0.25
0.27
0.002
<0.001
0.003
0.003

50.2
15.4
34.8
14.4
28.3
47.0

57.3
9.7
34.0
14.6
27.5
38.4

0.003
<0.001
0.72
0.93
0.69
<0.001

P value

<0.001
0.005
0.14
0.004
<0.001

0.54
<0.001

P value by independent t-test or Χ2.
Abbreviations: RDCI, Rheumatic Disease Comorbidity Index; RA, rheumatoid arthritis; CCP,
cyclic citrullinated peptide; RF, rheumatoid factor; ACR, American College of Rheumatology;
MD-HAQ, multidimensional Health Assessment Questionnaire; ESR, erythrocyte sedimentation
rate; DAS28, 28-joint Disease Activity Score; CDAI, Clinical Disease Activity Index; DMARD,
disease-modifying antirheumatic drug; NSAIDs, non-steroidal anti-inflammatory drugs
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Table 2. Frequency of specific chronic lung disease comorbidities
Lung disease

N

% of Patients

Any HCUP-CCS chronic lung disease

554

27.0

HCUP-CCS, COPD and bronchiectasis

301

14.7

HCUP-CCS, asthma

62

3.0

HCUP-CCS, lung disease due to external agents

2

0.1

HCUP-CCS, other lower respiratory disease†

330

16.1

Physician entered, ILD‡

106

5.2

Physician entered, COPD

371

18.1

Abbreviations: HCUP-CCS, Healthcare Cost and Utilization Project-Clinical Classification
Software; COPD, chronic obstructive pulmonary disease; ILD, interstitial lung disease
† Most diagnostic codes for interstitial lung disease are included in this HCUP-CCS category
‡ ICD-9-CM: 495, 515-517, 714.81
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Table 3. Associations of chronic lung disease with all-cause mortality in RA
Age & Sex

Intermediate†

Fully adjusted‡

Chronic lung disease

1.80 (1.54, 2.11)

1.72 (1.41, 2.10)

1.51 (1.26, 1.81)

COPD & bronchiectasis

2.02 (1.60, 2.56)

1.89 (1.50, 2.38)

1.61 (1.39, 1.86)

Asthma

1.02 (0.47, 2.17)

1.11 (0.49, 2.53)

0.77 (0.23, 2.54)

Other lower respiratory

1.52 (1.45, 1.59)

1.47 (1.35, 1.60)

1.32 (1.27, 1.36)

COPD

1.82 (1.43, 2.30)

1.70 (1.34, 2.16)

1.48 (1.16, 1.90)

Interstitial lung disease

1.99 (1.35, 2.94)

1.90 (1.26, 2.86)

1.90 (1.23, 2.96)

HCUP-CCS

Physician entered

Values are hazard ratios and 95% confidence intervals.
†Intermediate model includes age, sex, race, and smoking status.
‡Fully adjusted model includes covariates from intermediate model and multidimensional
Health Assessment Questionnaire, 28-joint Disease Activity Score, baseline DMARDs,
baseline prednisone use.
Abbreviations: HCUP-CCS, Health Care Cost and Utilization Project Clinical Classification
Software; COPD, chronic obstructive pulmonary disease
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Figure 2. Comparison of all-cause mortality risk between chronic lung and
cardiovascular comorbidity

Probability of survival by chronic lung disease (CLD) and cardiovascular disease (CVD)
status assessed during the 12 months prior to and following registry enrollment (neither
CVD nor CLD [black], CVD only [green], CLD only [blue], both CVD and CLD [red]). The
table contained within the figure shows hazard ratios for the association of CVD and
CLD with all-cause mortality in multivariable Cox models as well as the null interaction
between CVD and CLD.
Abbreviations: CLD, chronic lung disease; CVD, cardiovascular disease; DMARDs,
disease-modifying anti-rheumatic drugs
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Table 4. Comparison of mortality risk between specific categories of chronic lung
disease and cardiovascular disease comorbidity
HR (95% CI)
HCUP-CCS - COPD/bronchiectasis
No COPD or cardiovascular disease

Reference

COPD

1.76 (1.33, 2.32)

Cardiovascular disease

1.75 (1.50, 2.04)

COPD and cardiovascular disease

2.38 (1.88, 3.01)

HCUP-CCS - Other lower respiratory
No other lung disease or cardiovascular disease

Reference

Other lung disease

1.13 (0.85, 1.51)

Cardiovascular disease

1.56 (1.35, 1.79)

Other lung disease and cardiovascular disease

2.12 (1.81, 2.49)

Physician - COPD
No COPD or cardiovascular disease

Reference

COPD

1.61 (1.28, 2.02)

Cardiovascular disease

1.78 (1.57, 2.03)

COPD and cardiovascular disease

2.16 (1.54, 3.03)

Physician - Interstitial Lung Disease
No ILD or cardiovascular disease

Reference

ILD

2.18 (1.08, 4.41)

Cardiovascular disease

1.73 (1.58, 1.90)

ILD and cardiovascular disease

2.86 (1.76, 4.64)

Adjusted for age, sex, race, smoking status, multidimensional Health Assessment
Questionnaire, 28-joint Disease Activity Score, baseline DMARDs, baseline prednisone use
Abbreviations: CI, confidence interval; COPD, chronic obstructive pulmonary disease; HCUPCCS, Health Care Cost and Utilization Project Clinical Classification Software; HR, hazard
ratio; ILD, interstitial lung disease
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Table 5. Associations of DMARDs with mortality in RA subjects with and without
comorbid lung disease

Time-varying
Methotrexate
Leflunomide
Azathioprine
Hydroxychloroquine
Sulfasalazine
Biologic DMARD
Baseline
Methotrexate
Leflunomide
Azathioprine
Hydroxychloroquine
Sulfasalazine
Biologic DMARD

All subjects

Lung disease

No lung
disease

P
interaction

0.60
(0.50, 0.71)
0.79
(0.60, 1.04)
1.30
(0.82, 2.06)
1.08
(0.88, 1.33)
0.81
(0.68, 0.96)
0.60
(0.48, 0.75)

0.56
(0.42, 0.75)
0.67
(0.40, 1.11)
0.81
(0.33, 1.96)
0.96
(0.71, 1.30)
0.90
(0.72, 1.13)
0.64
(0.46, 0.88)

0.62
(0.52, 0.74)
0.94
(0.63, 1.42)
1.72
(1.21, 2.44)
1.20
(0.97, 1.48)
0.74
(0.60, 0.91)
0.54
(0.41, 0.70)

0.59

0.79
(0.59, 1.05)
0.86
(0.59, 1.26)
0.96
(0.66, 1.39)
0.93
(0.77, 1.14)
1.00
(0.80, 1.24)
1.05
(0.88, 1.25)

0.80
(0.53, 1.19)
0.88
(0.45, 1.70)
0.71
(0.28, 1.79)
0.68
(0.44, 1.04)
1.27
(0.93, 1.74)
1.09
(0.87, 1.37)

0.76
(0.56, 1.04)
0.94
(0.63, 1.41)
1.36
(0.70, 2.63)
1.19
(0.97, 1.47)
0.82
(0.54, 1.23)
0.97
(0.74, 1.28)

0.80

0.10
0.09
0.04
0.33
0.19

0.63
0.25
0.01
0.14
0.15

Values are hazard ratios and 95% confidence intervals.
Models adjusted for age, sex, race, smoking status, multidimensional Health Assessment
Questionnaire, 28-joint Disease Activity Score, chronic lung comorbidity (all-subjects only), and
baseline prednisone use.
Abbreviations: DMARD, disease-modifying anti-rheumatic drug
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Table 6. Associations of baseline DMARDs with mortality risk in RA subjects with
chronic lung comorbidity using propensity score adjustment
Propensity Score

Propensity Score

Continuous

Quintiles

Methotrexate

0.86 (0.44, 1.68)

0.87 (0.45, 1.70)

Leflunomide

0.90 (0.47, 1.72)

0.91 (0.50, 1.69)

Azathioprine

0.59 (0.15, 2.29)

0.59 (0.15, 2.34)

Hydroxychloroquine

0.87 (0.58, 1.31)

0.88 (0.58, 1.34)

Sulfasalazine

1.73 (1.03, 2.91)

1.67 (1.04, 2.69)

Biologic DMARD

0.90 (0.74, 1.08)

0.88 (0.74, 1.06)

Values represent hazard ratios and 95% confidence intervals
Abbreviations: DMARDs, disease-modifying anti-rheumatic drugs
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2.4

Discussion
Utilizing a cohort of U.S. Veterans with RA and adjusting for key confounders

(e.g., smoking status), we have demonstrated that chronic lung disease is associated
with reduced survival in RA. These findings were not limited to ILD, but included the
more common pulmonary manifestation of COPD. Among the most compelling findings,
the effect of chronic lung disease on mortality risk was comparable to that of comorbid
cardiovascular disease. Our results emphasize the importance of targeting chronic lung
diseases in RA patients with a similar urgency as has been proposed for cardiovascular
disease100 in order to achieve optimal long-term patient outcomes.
Prior studies of long-term outcomes in RA patients with lung disease have
primarily focused on ILD. There has been far less investigation into the long-term
outcomes for RA patients with obstructive lung diseases, despite evidence that the risk
of obstructive lung disease, such as COPD, is increased in RA patients.45,101 Only a few
small studies have examined the survival of RA patients with non-ILD pulmonary
manifestations, namely bronchiectasis and bronchiolitis. While the comparison group
varied between these studies, findings were suggestive of an increased mortality
risk.64,85,86 Our study not only confirms the findings of increased mortality with non-ILD
lung diseases, but expands on these observations. We studied over 2,000 RA patients
of which 27% had chronic lung disease and found a 51% increase in mortality for those
with any chronic lung disease relative to RA patients without. Those with chronic lung
disease were also more likely to die from lung disease (22.3% in those with chronic lung
disease vs. 9.9% in those without). While physician coding for ILD numerically carried
the highest risk of death in our study (nearly 2-fold higher than no lung disease),
COPD/bronchiectasis and other lower respiratory disease codes were associated with
an increased risk of death by 32-61% in RA patients. These results clearly indicate that
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non-ILD pulmonary manifestations are a major determinant of mortality risk in RA.
Furthermore, these results are in line with those from the general population where risk
of death was increased 1.6-fold for moderately severe COPD and 1.7-fold for restrictive
lung disease.102
The heightened risk of cardiovascular disease and cardiovascular diseaserelated mortality in RA has been well established.26,41,92 As a result, numerous efforts
have been undertaken to enhance the identification of cardiovascular disease and its
risk factors as well as treating both RA and modifiable risk factors as a means of
preventing premature cardiovascular disease mortality.100 In fact, recent reports suggest
these efforts may be effectively narrowing the current gap in cardiovascular disease
incidence between RA patients and the general population.40 Building on prior studies
identifying respiratory-related mortality as the most overrepresented cause of death in
RA,26,27 we have illustrated that comorbid lung disease carries a similar mortality risk as
comorbid cardiovascular disease. Thus, our findings provide support for the concept that
researchers and clinicians alike should aggressively target the identification and
treatment of lung disease in RA as well as its risk factors, as has been previously done
in cardiovascular disease. It should be noted, however, that these efforts could render
fewer gains than efforts focused on cardiovascular disease because of the limited
interventions that are currently available (e.g., smoking cessation and oxygen
supplementation). Unfortunately, data suggesting aggressive immunomodulatory
therapy improves survival in RA patients with chronic lung disease is lacking, in contrast
to some findings with cardiovascular disease-related mortality in RA.103
Selecting optimal DMARDs in RA patients with chronic lung disease is
challenging. There is concern that select DMARDs could exacerbate pre-existing lung
disease or cause pulmonary toxicity. Pre-existing lung disease is a risk factor for
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methotrexate pneumonitis,104 and, as suggested in the current study, individuals with/atrisk-for lung disease are often channeled to alternative therapies, such as leflunomide.78
However, there is limited evidence to support or refute these safety concerns, making it
critically important to evaluate the risk of poor long-term health outcomes with DMARDs
in RA patients with chronic lung disease. Reassuringly, our analyses suggest that
chronic lung disease does not appear to differentially impact the mortality risk
attributable to most DMARDs, including methotrexate and bDMARDs. These findings of
similar mortality risk in those with and without lung disease were robust to alternate
definitions of DMARD use (baseline vs. time-varying) as well as statistical models (Cox
models with multivariable adjustment vs. propensity score adjustment). As this is an
observational study design in which treatment selection was informed rather than
randomly selected, our observations should be interpreted as associations and not
causal evidence. Moreover, we examined mortality risk stratified by a composite chronic
lung disease measure. Therefore, future work will be needed to determine if there is a
differential mortality risk with DMARDs based on specific sub-types of chronic lung
disease in RA.
There are limitations to our study. Because our primary objective was to evaluate
survival following lung disease, we ascertained lung disease at cohort inception. Left
censoring may have occurred and lung disease occurring during follow-up was not
included, but these would be anticipated to bias the risk of mortality towards the null.
Furthermore, the insidious onset of lung disease makes it difficult to clearly define
“incident” vs. “prevalent” lung disease and will need to be the subject of future studies.
We assessed lung disease using diagnostic codes and categorized specific lung
diseases using the HCUP-CCS. While this is a standardized, freely accessible
classification software for diagnostic codes, it provides only limited classification of
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chronic lung diseases and has the potential to misclassify specific lung diseases.
However, we also examined diagnoses of COPD and ILD annotated by the treating
rheumatologist, with resulting COPD findings that were generally in agreement with
results based on HCUP-CCS classification. Given the retrospective nature of these
analyses, we were unable to apply American Thoracic Society/European Respiratory
Society guidelines for ILD classification.105 Our rates of chronic lung disease are higher
than others have reported,46 which likely reflects the male predominance and frequent
smoking history of our cohort and the VA population, and thus may limit generalizability.
Data regarding the severity of lung disease, imaging findings, and PFTs were not
available. While we adjusted for smoking status at the time of enrollment, data was not
available regarding duration, dose, or intensity of tobacco exposure as well as changes
in tobacco use that may have occurred during follow-up. Due to limited use of non-TNF
bDMARDs in those with chronic lung disease in our sample, we grouped all bDMARDs
together. Thus, future studies are needed to adequately assess the mortality risk with
individual bDMARDs.
Our study has numerous strengths including its cohort design and unique study
population enriched with chronic lung disease. Moreover, these analyses leveraged
robust data including longitudinal RA disease measures and functional status,
autoantibodies, and enrollment smoking status, all which could be potential confounders
that were adjusted for in multivariable analyses. We linked the clinical data within the
VARA registry to the National Death Index to assess vital status and with administrative
VA data to capture diagnostic codes related to usual care. Finally, we utilized the HCUPCCS, readily available to other researchers for use in studying chronic lung disease in
RA using administrative data.
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In summary, we have demonstrated a greater risk of death for RA patients with
chronic lung disease that is similar in magnitude to that of cardiovascular disease and
not limited to ILD. Reassuringly, methotrexate and bDMARD use, as occurring in regular
care, were not observed to impart a higher risk of mortality in RA patients with chronic
lung disease. While future studies should expand on our findings with further
characterization of lung disease that includes imaging findings and pulmonary function
testing, our study importantly brings to attention the poor prognosis that accompanies
chronic lung disease in RA.
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CHAPTER 3: IDENTIFICATION OF INTERSTITIAL LUNG DISEASE
WITH BIOLOGY
3.1

Background
ILD is a major determinant of poor long-term outcomes in patients with RA, a

population which already suffers from premature mortality. Median survival following RAILD diagnosis has been reported to be as short as 3 years,57 and trends in mortality
related to RA-ILD do not appear to be declining.84 The estimated prevalence of clinically
apparent ILD is 5-15% in RA patients, with up to 30% having subclinical disease on
high-resolution CT.57,65,84,106 Contributing to the wide-ranging epidemiologic estimates is
the difficulty in establishing the diagnosis of RA-ILD, which relies on a multidisciplinary
evaluation that often includes pulmonary function testing, high-resolution CT of the
chest, and/or lung biopsy.44,105 With a poorly understood pathogenesis and the
development of clinical symptoms well after radiologic or physiologic abnormalities have
established,65,107 delays in diagnosis of RA-ILD are commonplace. These delays in
detection may be particularly harmful if substantial irreversible decline occurs before
effective management or other preventative strategies are initiated.
Recognizing the diagnostic uncertainties and associated diagnostic delays, there
have been efforts to identify biomarkers capable of accurately identifying patients with,
or at risk of developing, RA-ILD. Candidate biomarkers have included Krebs von den
Lungen-6, MMP-7, IP-10, PARC, SP-D, anti-cit-HSP90, and a MUC5B promoter
variant.62,69-72 While these have shown promise and have provided important insight into
putative pathways driving disease, the availability of these measures has yet to be
translated into clinical practice. Of the biomarkers reported to date, some appear to lack
specificity for RA-ILD, while others have been subject to limited testing in RA patients
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with other lung disease (such as COPD) or have not been applied more broadly to large
RA patient populations. Thus, there exists a need for ongoing identification and
characterization of biomarkers for RA-ILD.73
The pathophysiology of RA-ILD encompasses multiple complex, interrelated
processes - inflammation, autoimmunity, fibrosis, and oxidative stress.44,108 MAA adducts
are highly immunogenic products of oxidative stress with the potential to facilitate
tolerance loss in the absence of adjuvant.109 Antibody responses to MAA have been
described by our group in RA patients and are associated with both ACPA responses
and disease activity.9 Additionally, MAA co-localizes with citrulline and immune cells in
RA synovium. Moreover, both MAA and anti-MAA antibody expression are enriched in
RA synovial tissues.9,110 Beyond its potential contributions to articular disease, MAA has
been demonstrated to stimulate inflammation and fibrosis in airway epithelial cells in
animal models and in vitro.111,112 Recognizing the pro-inflammatory and pro-fibrotic
properties of MAA and our observations of increased anti-MAA antibody responses in
RA, we hypothesized that MAA expression and anti-MAA antibody concentrations would
be increased in RA-ILD. We tested this hypothesis by comparing circulating anti-MAA
antibody concentrations in patients with RA-ILD to other RA patients, including those
with other chronic lung conditions. Additionally, we examined MAA expression in lung
tissues from RA-ILD, other ILD (non-RA ILD), emphysema, and normal tissues,
assessing co-localization with other RA autoantigens as well as immune cells that have
been consistently implicated in RA pathogenesis.

3.2

Methods

Study population and samples
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Serum analyses were conducted among participants within the VARA registry.94
The VARA registry is a multi-center prospective observational study of US Veterans with
RA fulfilling the 1987 ACR criteria93 that includes patients from 13 sites. Participants
provided informed consent prior to enrollment, all sites obtained local institutional review
board approval, and this study obtained approval from the VARA Scientific Ethics and
Advisory Committee. At enrollment, participants’ demographics, smoking status,
education, disease onset, medications, and comorbidities were recorded. At enrollment
and follow-up visits, ACR core measures including the MDHAQ,113 28-joint tender and
swollen joint counts, patient and provider global assessments were collected, acute
phase reactants were measured, and composite disease activity measures were scored
(DAS28).114
Lung tissues were obtained from the National Heart, Lung, and Blood Institute
Lung Tissue Research Consortium (https://ltrcpublic.com/). Samples (n=3/group) were
obtained following a standard protocol from individuals with RA-ILD, ILD (non-RA; nonspecific interstitial pneumonia [n=2] and idiopathic pulmonary fibrosis [n=1]),
emphysema (pathologic diagnosis), and controls who underwent transplant procedures,
lung volume reduction surgery, or biopsies. The latter control samples were typically
collected during evaluation of suspected malignancy and had normal surrounding
tissues.
Characterization of lung disease in VARA
ICD 9th and 10th revision, codes (ICD-9: 515, 516.3, 516.8, 516.9, 714.8; ICD-10:
M05.1, J84.1, J84.9, J99.0) were used for initial ILD case finding within the VARA
registry.77,78,84,115 Inpatient and outpatient visit diagnoses in the Corporate Data
Warehouse were queried within the VA Informatics and Computing Infrastructure.116
Medical record review was performed within the Compensation and Pension Record
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Interchange for all participants with ≥2 outpatient or ≥1 inpatient diagnostic codes for
ILD. Diagnoses by provider specialty (pulmonologist, rheumatologist, and other),
imaging findings (CT and chest x-ray), lung pathology, PFT results, and corresponding
dates were abstracted. Participants were classified as RA-ILD if they had a
pulmonologist diagnosis and imaging findings of ILD or if they had a non-pulmonologist
diagnosis plus two of the following: CT or chest x-ray findings interpreted by the reading
radiologist as ILD, pathology from a lung biopsy consistent with ILD, or interpretation of
PFTs as restrictive by the reading pulmonologist. COPD (clinical diagnoses of chronic
bronchitis and emphysema) diagnoses were extracted from medical records and
recorded in the VARA registry by treating rheumatologists at the time of VARA
enrollment. Patients were categorized into one of three mutually exclusive groups: 1)
RA-ILD (with or without comorbid COPD), 2) those with COPD in the absence of ILD, 3)
neither RA-ILD nor COPD. Recognizing that pathophysiologic processes, radiologic and
physiologic abnormalities, and clinical symptoms precede a formal diagnosis of ILD
(resulting in diagnostic delays), a two-year span following VARA enrollment (time of
serum collection) was used for classifying prevalent ILD.65,107 We excluded those with
indeterminate ILD (physician diagnosis, CT evidence, or biopsy findings but not fulfilling
the aforementioned algorithm) (Figure 3).
Measurement of serum and tissue analytes
Anti-MAA antibodies (IgA, IgM, and IgG isotypes) were measured by ELISA in
VARA participants using banked serum from enrollment, and reported in relative units
(RU) as previously described.9 We categorized anti-MAA antibody values into quartiles
to assess trends over the range of values as well as dichotomizing the anti-MAA
antibody isotypes into high vs. low concentrations, with the upper three quartiles being
considered high (approximating the frequency of other RA-related autoantibodies
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including both anti-CCP and RF). Anti-CCP antibodies were measured using a second
generation ELISA while RF was measured by nephelometry.99
Lung tissues were stained for MAA using an in-house MAA-specific rabbit
polyclonal antibody that was labeled with a Zenon 405 reporter (Molecular Probes,
Eugene, Oregon) and citrullinated proteins using a citrulline-specific mouse IgM
monoclonal antibody, clone F95 (Millipore, Temecula, CA). A Cy™3-conjugated
AffiniPure F(ab')2 fragment goat anti-mouse IgM, μ chain specific (Jackson Immuno
Research, West Grove, PA) was used as the detection antibody for the F95. Immune
cell types (macrophages, T cells, and B cells) were stained using antibodies to CD68
(polyclonal ALEXA FLUOR 594), CD3 (polyclonal ALEXA FLUOR 647), CD19
(polyclonal ALEXA FLUOR 647), and CD27 (polyclonal ALEXA FLUOR 594) (Bioss,
Woburn, MA). Tissues were incubated with isotype controls using a rabbit IgG
conjugated to ALEXA FLUOR 594 or 647 (Bioss). Based on prior analyses of paired lung
and synovial tissues,55 we also stained for extra-cellular matrix proteins: type II collagen
(polyclonal ALEXA FLUOR 488), vimentin (polyclonal ALEXA FLUOR 647), and
fibronectin (polyclonal ALEXA FLUOR 555) (Bioss). Tissues were imaged using a
confocal laser scanning microscope and staining was quantified using pixel densities, as
in prior studies.9,110
Statistical analyses
Baseline characteristics were compared between those with RA-ILD, RA+COPD,
and RA alone using chi-square or ANOVA. Anti-MAA antibodies were compared
between groups using Kruskal Wallis tests with Dunn’s post-hoc including a Bonferroni
correction. Two multivariable logistic regression models assessed the association
between anti-MAA antibody and RA-ILD status (combining RA+COPD with RA alone as
the comparator group because there were not significant differences in anti-MAA
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antibody concentration between these groups in unadjusted comparisons) with
covariates being specified a priori. The first (model A) adjusted for known patient
characteristics associated with RA-ILD: age, sex, race, and smoking status. The second
(model B) included covariates from model A in addition to RA-specific factors reported to
be associated with ILD: anti-CCP antibody positivity and disease activity
(DAS28).48,57,66,67 Anti-MAA antibody isotypes were tested in separate models because
of collinearity. Missing data were handled by complete-case analysis with complete data
available for >98% of participants.
Tissue staining of MAA, citrulline, immune cells, and extracellular matrix proteins
was compared between RA-ILD, other ILD, emphysema, and normal tissue controls via
ANOVA with a post-hoc Tukey’s to account for multiple comparisons. Co-localization of
MAA with immune cells and extracellular matrix proteins was determined using the Fiji
plugin, Coloc 2 in Image J, as previously reported.110 To confirm the validity of this
approach, we also measured co-localization between MAA and citrulline using Zen blue
software (Zeiss, Thornwood, NY) in normal and RA-ILD tissues. Pearson correlations
were compared across groups using ANOVA. Results were consistent between both
approaches (r Coloc2: normal=0.12, RA-ILD=0.79, P < 0.001; r Zen blue: normal=0.19,
RA-ILD=0.72, P < 0.001). Thus, the remainder of co-localization analyses were
completed using Coloc 2 in Image J. P values < 0.05 were considered statistically
significant. Analyses were completed using Stata v15 (StataCorp, College Station, TX).

3.3

Results

Study cohort derivation and characteristics
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Of 2,695 patients in the VARA registry, 1,885 had anti-MAA antibody
measurements from a prior study (measured on the entire cohort at that time9).
Diagnostic code screening and subsequent chart review confirmed 90 prevalent ILD
cases; an additional 63 participants were excluded because of indeterminate ILD status
(Figure 3). Baseline characteristics of the eligible participants (n=1,823) in the VARA
registry stratified by lung disease status are shown in Table 7. Those with RA-ILD were
older, more often male, have at least a high school education, seropositive, and to have
received bDMARDs or prednisone. Methotrexate use was less frequent in those with
RA-ILD. RA patients with COPD were less likely to be Caucasian, to have a high-school
education, and were more likely to be current smokers.
Characteristics of RA-ILD cases are shown in Table 8. The vast majority of
cases were confirmed based on a pulmonologist diagnosis (97.8%) and CT evidence
(94.4%). Restrictive PFTs were present in 60.0% and biopsy confirmation was present
for 13.3%. ILD was present for a mean of 2.3 years prior to enrollment and attributed to
RA in 93.3% of cases. ILD pattern was reported for only 38.9% of cases, with usual
interstitial pneumonia being the most common pattern.
Serum anti-MAA antibody and RA-ILD
Median serum concentrations of IgA and IgM anti-MAA antibody were higher
among those with RA-ILD than RA alone (Table 9; all P < 0.05). Additionally, median
serum concentrations of IgM anti-MAA antibody were also significantly higher in RA-ILD
patients (median 3,582 RU) than patients with RA+COPD (median 2,332 RU; P = 0.01).
IgG anti-MAA antibody was not significantly different between RA-ILD, RA+COPD, and
RA alone (P = 0.09).
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After multivariable adjustment for patient characteristics and RA-related factors,
higher quartiles of IgA and IgM anti-MAA antibody remained significantly associated with
RA-ILD (Table 10). Notably, inclusion of anti-CCP antibody positivity and DAS28 in
multivariable models had minimal impact on the associations between anti-MAA
antibody and RA-ILD. High values of IgA anti-MAA antibody, defined by the upper three
quartiles, were associated with a more than 2-fold higher odds of RA-ILD (odds ratio
[OR] 2.09; 95% CI 1.11-3.90 in fully adjusted model) in the absence of a dosedependent relationship across quartiles (P for trend = 0.07). As with IgA isotypes, higher
values of IgM anti-MAA antibody were also significantly associated with RA-ILD (OR
2.23; 95% CI 1.19-4.15 in fully adjusted model) but demonstrated a dose-dependent
relationship between anti-MAA antibody quartiles and prevalent ILD (P for trend =
0.004). The highest two quartiles of IgG anti-MAA antibody trended towards being
associated with RA-ILD, though this did not reach statistical significance (P = 0.15 and
0.17). We assessed all three isotypes together by categorizing individuals according to
the number of positive anti-MAA antibody isotypes. Individuals with 3 positive isotypes
had 2.5-fold higher odds of RA-ILD than those with 0-1 positive isotype (OR 2.56; 95%
CI 1.29-5.09).
Lung tissue patient characteristics
Mean (standard deviation [SD]) age of participants with tissue samples was 56.4
(11.7) years with 75.0% being female. A smoking history was present overall in 66.7% of
patients (100% of other ILD and emphysema, 33.3% of normal and RA-ILD). Mean (SD)
pack-years of smoking history was 17.5 (14.3). Anti-CCP antibodies and IgM RF were
positive in two of three RA-ILD patients. Anti-CCP antibodies, but not IgM RF, were
additionally detected in one of three other ILD patients.
MAA and citrulline expression in lung tissue
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MAA expression was highest in RA-ILD lung tissues (Figure 4A and 4B, P <
0.001 vs. all other groups). Citrulline was also higher in RA-ILD lung tissues (Figure 4C
and 4D) relative to normal and other ILD lung tissues (P < 0.001), but not significantly
different than emphysematous lung tissue (P = 0.91). Expression of both MAA and
citrulline was highly co-localized in RA-ILD lung tissue (Figure 4E and 4F; r=0.79),
significantly higher than in lung tissues from other patient groups (P < 0.001 vs. normal
[r=0.12] and other ILD [r=0.38], P = 0.002 vs. emphysema [r=0.47]).
Co-localization of MAA and citrulline with immune cells in lung tissue
Staining for CD68+ macrophages and CD3+ T cells was higher in all diseased
tissues relative to normal lung tissue (Figure 5A; all P < 0.01). Macrophage staining was
higher in other ILD than in RA-ILD and emphysema (P < 0.05). In contrast, CD19+ and
CD27+ (memory) B cells were more abundant in RA-ILD lung tissues than tissues from
all other groups (P ≤ 0.02). There was minimal to moderate co-localization between MAA
and macrophages or T cells (r values 0.12 to 0.54), with no significant differences
between lung tissue types (Figure 5B; all P > 0.10). In contrast, we observed strong colocalization of MAA with CD19+ B cells, with the highest correlation identified in RA-ILD
(r=0.78; P ≤ 0.02 vs. all other lung tissues). Co-localization of MAA with CD27+ B cells
was more modest (r vales 0.02 to 0.30), with other ILD yielding the highest correlation
(r=0.30; P ≤ 0.004 vs. RA-ILD and normal, P = 0.06 vs. emphysema).
Citrulline co-localized with CD68+ macrophages to a greater degree in RA-ILD
(Figure 5C; P = 0.04) and emphysema (P < 0.001) than in normal lung tissue. There
was minimal co-localization of citrulline with T cells (r vales 0.07 to 0.18). There was
moderate co-localization of citrulline with CD19+ B cells in both RA-ILD (r=0.53) and
other ILD (r=0.44) that exceeded the degree of co-localization observed for emphysema
and normal tissues (P < 0.01). Co-localization of citrulline with CD27+ (memory) B cells
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was highly prevalent in diseased lung tissue (all P < 0.001 vs. normal) but not different
between specific types of diseased lung tissues (all P > 0.29).
Co-localization of MAA with extracellular matrix proteins
Staining for type II collagen was higher in RA-ILD and other ILD than normal lung
tissues (Figure 6A; P ≤ 0.002). However, co-localization of MAA with type II collagen
was greater in RA-ILD (r=0.72) compared with other lung tissues (Figure 6B; r=0.120.49; all P ≤ 0.02). Fibronectin staining was higher in both RA-ILD and emphysema
relative to normal lung tissues (P ≤ 0.03) with only weak co-localization of MAA and
fibronectin in RA-ILD (r=0.21). Vimentin staining was higher in all diseased lung tissues
compared to normal lung tissue (all P ≤ 0.03), although co-localization of MAA and
vimentin was higher in RA-ILD than other ILD (P < 0.001) without significant differences
compared to other lung tissues (all P ≥ 0.09).
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Figure 3. Serum anti-MAA antibody study cohort derivation

Participants in the Veterans Affairs Rheumatoid Arthritis (VARA) registry with available
anti-malondialdehyde acetaldehyde adduct (MAA) antibody measurement were
screened for interstitial lung disease (ILD) using outpatient and inpatient diagnostic
codes. Detailed chart review was completed to confirm ILD diagnosis if ≥2 outpatient or
≥1 inpatient diagnostic codes were identified (*), confirming 90 ILD cases.
Abbreviations: COPD, chronic obstructive pulmonary disease; ILD, interstitial lung
disease; MAA, malondialdehyde-acetaldehyde adduct; VARA, Veterans Affairs
Rheumatoid Arthritis registry
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Table 7. Baseline characteristics of VARA participants by lung disease status
Overall

RA-ILD

RA + COPD

RA alone

(n=1823)

(n=90)

(n=294)

(n=1439)

63.5 (11.0)

67.0 (9.9)

65.8 (9.7)

62.8 (11.3)

<0.001

Male sex

90.1

95.6

92.5

89.2

0.05

Caucasian

76.7

76.7

83.7

76.2

0.02

HS education

86.4

91.7

78.9

87.5

<0.001

Age, years

Smoking

P value

<0.001

status
Current

26.1

27.8

31.0

25.1

Former

53.4

58.9

58.8

52.0

Never

20.4

13.3

10.2

23.0

BMI, kg/m2

28.4 (5.7)

27.8 (5.1)

28.3 (6.1)

28.4 (5.7)

0.67

RDCI score

1.9 (1.5)

3.2 (1.6)

3.9 (1.1)

1.4 (1.2)

<0.001

RA duration

11.1 (11.5)

13.3 (13.1)

11.1 (11.9)

10.9 (11.3)

0.17

SE positive

68.8

65.6

73.0

68.2

0.22

Anti-CCP

77.3

86.7

80.3

76.0

0.03

79.8

92.2

80.6

78.9

0.009

MDHAQ

0.9 (0.6)

0.9 (0.5)

1.1 (0.6)

0.9 (0.6)

0.004

DAS28

4.0 (1.6)

4.1 (1.4)

4.4 (1.5)

3.9 (1.6)

0.003

Methotrexate

51.9

21.0

47.6

54.7

<0.001

Biologic

22.9

30.0

16.3

23.8

0.005

Prednisone

43.5

63.0

43.1

42.4

0.01

positive
RF positive

Values mean (SD) or %. P values test of group differences by ANOVA or chi-square tests
Abbreviations: RA, rheumatoid arthritis; ILD, interstitial lung disease; COPD, chronic
obstructive pulmonary diseases; HS, high-school; BMI, body mass index; RDCI, rheumatic
disease comorbidity index; SE, shared epitope; anti-CCP, anti-cyclic-citrullinated peptide
antibody; RF, rheumatoid factor; MDHAQ, multidimensional health assessment questionnaire;
DAS28, 28-joint disease activity score; VARA, Veterans Affairs Rheumatoid Arthritis Registry
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Table 8. Characterization of RA-ILD cases
Mean (SD) or N (%) of Validated ILD
cases
N

90

CT evidence of ILD

88 (97.8)

Pulmonologist diagnosis

85 (94.4)

Restrictive PFTs

54 (60.0)

Biopsy confirmation

12 (13.3)

Duration of ILD, years

2.3 (3.8)

Reason for ILD includes RA

84 (93.3)

Pattern of ILD
Usual interstitial pneumonia

26 (28.9)

Non-specific interstitial pneumonia

4 (4.4)

Other

5 (5.6)

Unknown/missing

55 (61.1)

PFT closest to enrollment (n available)
FVC % predicted (n=62)

75.1 (17.3)

FEV1 % predicted (n=63)

74.5 (17.1)

FEV1/FVC ratio (n=60)

74.8 (9.1)

TLC % predicted (n=42)

80.8 (19.9)

DLCO % predicted (n=58)

54.9 (17.3)

Abbreviations: CT, computed tomography; ILD, interstitial lung disease; PFT, pulmonary
function test; RA, rheumatoid arthritis; FVC, forced vital capacity; FEV1, forced expiratory
volume in 1 second; TLC, total lung capacity; DLCO, diffusion capacity
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Table 9. Anti-MAA antibody concentrations by lung disease status in RA subjects
Anti-

RA-ILD

RA + COPD

RA alone

P value*

body

(n=90)

(n=294)

(n=1439)

IgA

891 (501, 1624) †

869 (399, 1665) †

689 (323, 1440)

0.005

IgM

3582 (1302, 11141) † ±

2332 (888, 5649)

2094 (843, 5610)

0.005

IgG

2226 (1353, 3781)

1996 (1039, 3701)

1868 (943, 3415)

0.09

Values represent median (interquartile range) in relative units (RU)
* P value by Kruskal Wallis (unadjusted comparisons)
† p < 0.05 vs. RA alone (Dunn’s test with Bonferroni correction)
± p < 0.05 vs. RA + COPD (Dunn’s test with Bonferroni correction)
Abbreviations: RA, rheumatoid arthritis; ILD, interstitial lung disease; COPD, chronic
obstructive pulmonary disease; anti-MAA, anti-malondialdehyde acetaldehyde adduct
antibodies; RU, relative units
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Table 10. Multivariable associations of anti-MAA antibody with RA-ILD

Quartiles

Model A. Age, sex, race,
smoking status
(n=1820)
OR (95% CI)
P value

Model B. Model A + anti-CCP
positivity and DAS28
(n=1792)
OR (95% CI)
P value

IgA anti-MAA
Quartile 1

Referent

-

Referent

-

Quartile 2

2.27 (1.12, 4.59)

0.02

2.09 (1.03, 4.27)

0.04

Quartile 3

2.20 (1.09, 4.43)

0.03

2.07 (1.02, 4.18)

0.04

Quartile 4

2.26 (1.12, 4.56)

0.02

2.10 (1.04, 4.25)

0.04

P trend

0.04

0.07

IgM anti-MAA
Quartile 1

Referent

-

Referent

-

Quartile 2

1.87 (0.91, 3.86)

0.09

1.84 (0.89, 3.81)

0.10

Quartile 3

2.26 (1.11, 4.60)

0.03

2.08 (1.02, 4.27)

0.05

Quartile 4

2.93 (1.49, 5.78)

0.002

2.73 (1.38, 5.41)

0.004

P trend

0.001

0.004

IgG anti-MAA
Quartile 1

Referent

-

Referent

-

Quartile 2

1.34 (0.69, 2.61)

0.39

1.33 (0.68, 2.59)

0.41

Quartile 3

1.73 (0.91, 3.27)

0.09

1.61 (0.84, 3.06)

0.15

Quartile 4

1.67 (0.88, 3.18)

0.12

1.58 (0.83, 3.02)

0.17

P trend

0.09

0.14

Antibody positive
IgA anti-MAA

2.24 (1.20, 4.18)

0.01

2.09 (1.11, 3.90)

0.02

IgM anti-MAA

2.35 (1.26, 4.38)

0.007

2.23 (1.19, 4.15)

0.01

IgG anti-MAA

1.58 (0.91, 2.75)

0.11

1.50 (0.86, 2.63)

0.15

* Antibodies tested in separate logistic regression models
Abbreviations: MAA, malondialdehyde-acetaldehyde adducts; RA, rheumatoid arthritis; ILD,
interstitial lung disease; anti-CCP, anti-cyclic-citrullinated peptide antibody; DAS28, 28-joint
disease activity score; OR, odds ratio; CI, confidence interval
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Figure 4. Lung tissue expression of MAA, citrulline, and their co-localization in
RA-ILD and other lung diseases

Expression of malondialdehyde-acetaldehyde adducts (MAA) measured by pixel density
(Figure 4A) and representative immunohistochemistry staining of lung tissues for MAA
(Figure 4B). Tissue expression (Figure 4C) and immunohistochemistry staining of lung
tissues for citrulline (Figure 4D) are also shown. The co-localization of MAA and citrulline
was quantified through a correlation coefficient of their staining (Figure 4E) and
overlapping immunohistochemistry staining are shown (Figure 4F).
Abbreviations: MAA, malondialdehyde-acetaldehyde adducts; CIT, citrulline; RA-ILD;
rheumatoid arthritis interstitial lung disease; ILD, interstitial lung disease.

47

Figure 5. Co-localization of MAA and citrulline with immune cells in lung tissue
from RA-ILD and other lung diseases

Tissue staining for macrophage (CD68), T cells (CD3), and B cells (CD19 and CD27) for
RA-ILD, other ILD, emphysema, and healthy control lung tissues (Figure 5A). Colocalization of MAA with macrophage, T cells, and B cells in different lung tissues (Figure
5B). Co-localization of citrulline with macrophage, T cells, and B cells in different lung
tissues (Figure 5C).
Abbreviations: MAA, malondialdehyde-acetaldehyde adducts; CIT, citrulline; RA-ILD;
rheumatoid arthritis interstitial lung disease; ILD, interstitial lung disease.
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Figure 6. Co-localization of MAA with extracellular matrix proteins in lung tissue
from RA-ILD and other lung diseases

Tissue staining for extracellular matrix proteins (type II collagen, fibronectin, and
vimentin) in RA-ILD, other ILD, emphysema, and healthy control lung tissues (Figure
6A). Co-localization of MAA with extracellular matrix proteins in different lung tissues
(Figure 6B).
Abbreviations: MAA, malondialdehyde-acetaldehyde adducts; CIT, citrulline; RA-ILD;
rheumatoid arthritis interstitial lung disease; ILD, interstitial lung disease.

49

3.4

Discussion
ILD complicates the disease course for 5-15% of RA patients,57,65,84,106 resulting

in potentially devastating complications of functional decline and premature mortality.
Enhancing the identification of RA-ILD is an important area of translational research in
RA, with serum biomarkers emerging as candidates to fulfill this need. For the first time,
we investigated serum anti-MAA antibody as a potential biomarker of RA-ILD and
characterized the expression of MAA in lung tissues from RA-ILD patients. We found
that IgA and IgM anti-MAA antibody concentrations were higher in RA-ILD patients than
in other RA patients, including those with other forms of chronic lung disease (IgM only).
In parallel studies, we found MAA adduct expression to be higher in RA-ILD lung tissues
than in other chronic lung diseases including other ILD. Importantly, MAA adducts
demonstrated marked co-localization with citrulline, CD19+ B cells, and type II collagen
that was preferential to RA-ILD lung tissues. This study is among the first to characterize
a biomarker for RA-ILD that has leveraged a comparator population incorporating RA
patients with other chronic lung diseases that may be overrepresented in RA.45
Together, our findings suggest that MAA modified proteins and resulting immune
responses may serve as useful biomarkers for RA-ILD and that MAA modified proteins
may contribute to the pathogenesis of RA-ILD.
Serum biomarkers have been increasingly investigated for their potential role in
identifying RA-ILD. Protein candidates have included widely used biomarkers in RA
(anti-CCP antibody and RF),48,66,117 novel autoantibodies (anti-cit-HSP90),70
cytokines/chemokines (MMP-7, IP-10, PARC),71,72 and SP-D.72 Oxidative stress
represents a potentially relevant biologic pathway that has not been harnessed in prior
biomarker studies of RA-ILD. Oxidative stress, a disruption of the balance of free
radicals and antioxidants, is believed to be intimately involved with the development of
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diffuse lung diseases because of the continuous exposure to oxygen, high surface area,
and robust blood supply in the lungs. MAA, which is generated from lipid peroxidation
during oxidative stress, has the potential to link multiple pathways implicated in RA-ILD
pathogenesis - oxidative stress, autoimmunity, inflammation, and fibrosis. MAA induces
tolerance loss,109 elicits robust adaptive immune responses (anti-MAA antibody), and
upregulates pro-inflammatory and pro-fibrotic pathways.111,112 Our study importantly
begins to characterize lung tissue expression of MAA in different lung disease states as
well as serum anti-MAA antibody responses in RA patients with and without lung
diseases. Confirming our hypothesis, MAA expression in lung tissue and serum antiMAA antibody concentrations were highest in RA-ILD patients.
Although we found over 2-fold higher odds of ILD among RA patients with serum
IgA or IgM anti-MAA antibody concentrations in the upper three quartiles, it is important
to note that these antibodies are not specific for RA-ILD. Anti-MAA antibodies are
present in RA patients in the absence of chronic lung disease, as well as other disease
states.10 However, specificity of a candidate biomarker of RA-ILD may be less important
than initial case finding, given that CT and PFTs are ultimately needed to confirm the
presence and subtype of ILD (which influences prognosis). Translating these novel
findings of anti-MAA antibody in RA-ILD into clinical practice will require additional work.
As several other serum biomarkers have shown promise for identifying RA-ILD,
biomarker panels that include anti-MAA antibody and other analytes are likely to
outperform models based on a single analyte. To date, the measurement of anti-MAA
antibody has leveraged the use of adducted albumin as the plating antigen, a protein
that has no known pathogenic role in RA. Identification of the precise antigenic targets of
anti-MAA antibody is likely to allow for improved assay performance in identifying RA
patients with ILD. Finally, our current results assessed the ability of anti-MAA antibody to
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identify established RA-ILD. Future study will need to assess the value of anti-MAA
antibody for predicting future RA-ILD risk. This could be of even greater value than
identifying prevalent RA-ILD, as it may identify patients with earlier disease that might be
more amenable to therapeutic and/or preventative interventions,118 though data
specifically in RA-ILD is lacking.
Paralleling serum findings, staining for MAA adducted antigens was highest in
lung tissues from RA-ILD patients. Importantly, this occurred preferentially in RA-ILD
lung tissue, with significantly higher staining than in other ILD and emphysema. In
contrast to MAA, citrulline was expressed in both RA-ILD and emphysema. Although the
specificity of serum anti-CCP antibodies for RA approaches 96%,119 others have
similarly found citrulline and ACPA responses to accompany chronic obstructive lung
diseases in the absence of RA.49,120,121 Given the strong co-localization of MAA with
citrullinated antigens in RA-ILD, we postulate that MAA could act as a “second hit” in RA
pathogenesis by facilitating tolerance loss to co-localized citrullinated antigens. Although
further testing will be needed to address this hypothesis, the co-localization of CD19+ B
cells with MAA and citrulline would support the concept that these post-translational
changes (both of which likely result from injurious stimuli) conspire in autoantibody
generation. This is further supported by preliminary work in animal models suggesting
immunization with co-modified (MAA+citrulline) albumin leads to greater ACPA
responses than citrullinated-albumin alone.122 Finally, vimentin is an extracellular matrix
protein that has previously been shown to be a shared target of citrullination/ACPAs in
the synovium and lung.55 While we did not find vimentin expression to be increased in
RA-ILD compared to other lung conditions, we observed marked co-localization of MAA
with vimentin in RA-ILD lung tissues, co-localization that was significantly more robust
than that seen with other ILD.
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Our group has previously characterized anti-MAA antibodies in sera from RA and
other rheumatic and musculoskeletal disease patients.9,10 Circulating anti-MAA antibody
concentrations are higher in RA patients than those with osteoarthritis, are associated
with serum ACPAs, and are enriched within RA synovium.9,110 As we found in RA-ILD
lung tissues assessed in this study, MAA and citrulline co-localized in RA synovium.110
Also paralleling the RA-ILD lung findings from the present study, prior work by our group
has shown that MAA and citrulline both co-localize with B cells in the synovium.
However, there are differences in B cells implicated by site. In the synovium, MAA and
citrulline co-localized most strongly with CD27+ memory B cells.110 In the lung tissues
from RA-ILD patients, MAA co-localized most strongly with CD19+ B cells, but not with
CD27+ memory B cells. While future work will be needed to elucidate the temporal
evolution of immune responses to MAA, it is intriguing that immature B cells are
associated most strongly with MAA adduct expression in the lung given the emerging
evidence that the lungs may be a site of immune tolerance breakdown contributing to the
early development of RA.56
There are limitations to this study. The male predominance, Veteran status, and
lower prevalence of bDMARD use may affect generalizability. Collection of ILD data was
obtained retrospectively and not all data were available within the medical records. This
may underestimate the cross-sectional prevalence of ILD in the cohort (4.7%). However,
misclassification of ILD cases as non-ILD would bias our results towards the null.
Distinguishing between clinical and sub-clinical ILD cannot be definitive based on
retrospective classification. By confirming physician diagnoses in the medical records,
rather than relying on diagnostic codes or diagnostic testing alone, we believe the
majority of ILD cases were clinically evident. Given the low frequency with which ILD
pattern (usual interstitial pneumonia vs. non-specific interstitial pneumonia vs. other) was
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specified, we were not able to compare anti-MAA concentrations by RA-ILD pattern.
Likewise, anti-MAA antibody measurements were not available for all registry
participants, which may also have reduced study power. Again, this should not have
introduced bias, as antibody measurements were performed on the entire cohort at the
time of the prior study without any relation to ILD status. Reflecting the prevalence of
seropositivity for RF and anti-CCP antibody, we dichotomized anti-MAA antibody as
being in the upper three quartiles. Only increasing IgM anti-MAA antibody quartiles were
more strongly associated with the presence of ILD. Further work will be needed to
determine clinically important cut-offs for these antibodies. Sample sizes were limited for
lung tissue studies, with lung tissues obtained from three individuals with each lung
condition, prohibiting multivariable analyses. One of the non-RA ILD patients had
detectable ACPAs but was not classified as RA. Given the cross-sectional nature of the
study, it is unknown if that patient later developed RA. This potential misclassification of
RA-ILD as non-RA ILD would only bias our results towards the null. Lung tissue samples
were not matched, so there may be unmeasured confounding.
There are important strengths to this study. We performed a detailed review of
the medical records to validate ILD diagnoses in RA patients from a well characterized
registry that includes robust data including many relevant covariates.94 We evaluated not
only serologic anti-MAA antibody concentrations, but also investigated tissue expression
of MAA and its co-localization with citrulline, immune cells, and extracellular matrix
proteins that have been consistently implicated in disease pathogenesis. Finally, we
characterized MAA and anti-MAA immune responses in RA-ILD by using comparators
that were free of lung disease in addition to comparators with other chronic lung
diseases.
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In conclusion, we found higher levels of serum IgA and IgM anti-MAA antibody to
be associated with RA-ILD in a large cohort of U.S. Veterans with RA. Lung tissue
expression of MAA is similarly higher in RA-ILD lung tissue where it co-localizes with
citrulline, CD19+ B cells, and extracellular matrix proteins. These findings suggest that
MAA immune responses could play an important role in the pathogenesis of RA-ILD and
anti-MAA antibodies may be promising serum biomarkers in the identification of this
extra-articular disease manifestation.
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CHAPTER 4: IDENTIFICATION OF INTERSTITIAL LUNG DISEASE
WITH BIOMEDICAL INFORMATICS
4.1

Background
ILD clinically affects between 5-15% of RA patients resulting in poor long-term

outcomes including reduced survival and greater functional disability.47,48,57 Given
disease heterogeneity and lack of well-characterized classification criteria for RA-ILD,
the case definitions used and prevalence estimates reported for RA-ILD are highly
variable between studies.47,57,65,123 Administrative data sources are increasingly being
utilized in RA outcomes research, primarily to facilitate investigations examining
predictors of disease-related outcomes or the safety and effectiveness of DMARDs.124
Yet, only a few studies have begun to leverage these large administrative databases to
study RA-ILD.63,77,78,84,125
Prior studies utilizing administrative databases for RA-ILD research have
constructed RA-ILD cohorts or identified ILD outcomes in RA patients using claims
databases,63,77,78 death records,84 or national patient registries.125 All have used
diagnostic codes for RA and ILD in combination, though additional requirements for RA
diagnosis such as DMARD receipt and specific ILD diagnostic codes selected has varied
between studies. To enhance specificity, authors have required ILD diagnostic tests77 or
excluded other causes of ILD (e.g., sarcoidosis, hypersensitivity pneumonitis,
pneumoconioses, etc.).63 However, the validity of these algorithms has received only
limited attention,126 hampering wider adoption of these methods for studying RA-ILD.
With validated ILD algorithms, large administrative datasets could be leveraged for
comparative effectiveness research and epidemiologic analyses, while deployment in
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electronic health records could enhance recruitment into patient registries or clinical
trials.
The objective of this study was to develop and evaluate the performance of
several different administrative algorithms for the identification of ILD in a multi-center
RA registry. We hypothesized that administrative algorithms that included multiple ILD
diagnostic codes, a pulmonologist diagnosis, procedure codes for CT of the chest, PFTs,
or lung biopsy, and exclusion of other causes of ILD would accurately classify RA-ILD
compared to a comprehensive review of medical records.

4.2

Methods

Patient selection
We selected subjects enrolled in the VARA registry, a multi-center, prospective
cohort study of U.S. Veterans with RA initiated in 2003.94 All subjects fulfilled the 1987
ACR criteria for RA.93 Participants provided informed consent prior to enrollment and all
sites (n=13) obtained local institutional review board approval. This study obtained
approval from the VARA Scientific Ethics and Advisory Committee.
To enrich the study sample with ILD cases, we performed stratified subsampling
through initial ILD screening. We queried national VA data in the Corporate Data
Warehouse to identify VARA participants with ≥1 inpatient or ≥2 outpatient ILD
diagnostic codes (>30 days apart) from health care providers (physicians, physician
assistants, and advanced practice nurses). ICD, 9th and 10th revision, Clinical
Modification codes were selected from those previously proposed to ascertain ILD status
or closely related codes (Appendix D).77,78,84,115,125,126 We performed detailed, systematic
medical record review on all subjects identified through initial screening (n=293) and a
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random sample of all VARA subjects not identified by the ILD screening method (n=243)
so as to be able to comment on the sensitivity of the selected ICD codes and ILD
algorithms.
ILD data abstraction
Data was abstracted from the electronic medical records using the
Compensation and Pension Record Interchange in a standardized fashion by three
rheumatologists blinded to the results of the administrative algorithms using Research
Electronic Data Capture (REDCap).127,128 Regardless of ILD screening status,
participants’ outpatient and inpatient clinical notes, imaging reports, pathology reports,
and PFT results from the earliest available date in the medical record were reviewed and
recorded. Data abstracted included pulmonologist diagnoses, other physician diagnoses,
chest CT results, chest x-ray results, PFT results, lung biopsy results, as well as dates
corresponding to the aforementioned items. To ensure consistency between reviewers,
charts were reviewed in sets of 5 in duplicate until >95% agreement on abstracted data
was obtained between reviewers. As our reference standard, participants were classified
as RA-ILD by medical record review using both stringent and relaxed ILD definitions.
The stringent definition classified participants as RA-ILD if they had a pulmonologist
diagnosis and imaging (chest CT or x-ray) findings of ILD or if they had a nonpulmonologist provider diagnosis plus two of the following: chest CT or x-ray findings
interpreted by the reading radiologist as ILD, pathology from a lung biopsy consistent
with ILD, or interpretation of PFTs as restrictive by the reading pulmonologist. The
relaxed ILD definition additionally classified subjects as ILD who had a provider
diagnosis of ILD (pulmonologist or non-pulmonologist) and either imaging findings
consistent with ILD or pathology demonstrating ILD.
Algorithm development
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We queried National VA data within the Corporate Data Warehouse from
January 1, 1999 to August 31, 2018 for all participants to obtain the necessary
components of each ILD algorithm. Data queried included inpatient and outpatient
encounters in the VA, inpatient and outpatient encounters occurring outside the VA and
billed to the VA, specialty of outpatient encounters, and outpatient and inpatient
procedures.
We tested the characteristics of possible administrative ILD algorithms in four
stages. In the first stage, we tested the performance of algorithms using different
encounter types (inpatient vs. outpatient) and frequency of ILD diagnostic codes (≥1 vs.
≥2). In stage 2, we compared different ICD-9 and ICD-10 code sets (Appendix D).
These code sets were created by removing ICD-9 and ICD-10 codes with descriptions
including “unspecified” or “other”, those pertaining to rheumatoid lung, and those not
consistently included in prior studies. Stage 3 testing compared algorithms that
incorporated additional data available in administrative datasets that may improve
algorithm specificity. These additional data were provider specialty on the ICD-9/10
diagnoses, and procedure codes for chest CT, PFTs, and lung biopsy procedures.
Current Procedural Terminology (CPT) and ICD Procedural Codes for chest CT and lung
biopsy were adapted from those used in IPF algorithms (Appendix E) 129,130. In addition
to CPT and ICD procedure codes, we also identified PFTs through the use of stop codes
in National VA data, which designate clinical services provided in PFT labs. In the final
stage (stage 4), we excluded other causes of ILD recorded after the final ILD diagnosis
using codes for pneumoconioses, radiation pneumonitis, hypersensitivity pneumonitis,
and other connective tissue diseases (Appendix F).
Statistical analysis
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Enrollment characteristics of the VARA patients selected for these analyses were
assessed descriptively and stratified by medical record review ILD classification status.
Agreement between ILD algorithms and medical record review classification was
assessed with percent agreement and Kappa statistics. Levels of agreement based on
the Kappa statistic were interpreted as near perfect (values of 0.8-1.0), substantial (0.60.8), moderate (0.4-0.6), fair (0.2-0.4), or slight (0.0-0.2).131 We also calculated the
sensitivity, specificity, positive predictive value (PPV), and negative predictive value
(NPV) along with 95% CIs for each algorithm, treating medical record classification as
the reference standard. All analyses accounted for the subsampling from the overall
VARA registry by the use of inverse probability weighting (R package CompareTests).132
This ensured that the prevalence of ILD in weighted analyses was consistent with the
overall cohort. Algorithm selection through each stage was based on optimal Kappa
values. Several sensitivity analyses were performed testing variations of administrative
ILD algorithms and using medical record ILD definitions with fewer requirements.
Analyses were conducted using Stata v15 (StataCorp, College Station, TX) and R
version 3.5.1 within the VA Informatics and Computing Infrastructure. We report our
study in accordance with proposed reporting guidelines for assessing the quality of
validation studies of health administrative data.133

4.3

Results

Enrollment characteristics
We identified 293 subjects in the VARA registry who met the initial ILD screening
criteria and randomly selected 243 VARA participants who did not screen positive for
ILD (Figure 7). Detailed medical record review performed on all 536 of these subjects
confirmed 182 and 203 ILD cases using stringent and relaxed ILD definitions,
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respectively. Patient characteristics were reflective of the overall VARA registry and the
VA population with a male predominance and mean age at enrollment in the 7th decade
of life (Table 11). Those with ILD were older, more frequently RF positive, less likely to
be treated with methotrexate, and more likely to receive prednisone at enrollment.
The majority of ILD cases occurred among those who screened positive for ILD
(97.3% stringent and 96.6% relaxed), had a pulmonologist diagnosis (94.5% stringent
and 84.7% relaxed), and had CT evidence of ILD (98.4% stringent and 96.1% relaxed)
(Table 11). Approximately half of the ILD cases were prevalent at the time of enrollment
into the registry, and the initial date of ILD diagnosis occurred after implementation of
ICD-10 in 17 cases (21 cases relaxed ILD definition). Among non-ILD cases,
pulmonologist ILD diagnosis was present in 1.4-1.5%, non-pulmonologist ILD diagnosis
was present in 8.5% (stringent) and 2.7% (relaxed), and CT evidence of ILD was present
in 11.3% (stringent) and 7.2% (relaxed).
Stage I: Frequency of diagnosis codes and encounter types
Performance of eight different algorithms (1A to 1H) reflecting differences in
frequency, encounter types, and date ranges for ILD diagnosis codes in classifying ILD
is shown in Table 12. Kappa was greatest for algorithms 1D (0.71) and 1F (0.70).
Performance was similar in classifying ILD with the relaxed definition (Kappa 0.71).
Sensitivity ranged from 76.3-81.7% and specificity ranged from 96.0-97.1%, but PPV of
these algorithms were modest (65.5-73.9%). Because of their equivalent performance,
Algorithm 1F, which required ≥2 diagnosis codes ≥30 days apart from either inpatient or
outpatient encounters, was selected for further testing.
Stage II: Diagnosis code selection
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Exclusion of ICD-10 codes J84.2 and J99 did not result in any difference in ILD
classification (Table 13). Exclusion of rheumatoid lung codes (ICD-9: 714.81; ICD-10:
M05.1x) minimally attenuated sensitivity and NPV while improving specificity and PPV.
Kappa was improved from the all-inclusive ICD code algorithm when rheumatoid lung
codes were excluded. Medical record review identified RA-related pleural effusions and
pulmonary nodules as reasons for these codes in the absence of ILD. Algorithm
performance measured by Kappa worsened when “unspecified” and “other” ILD codes
were excluded. Based on these performance characteristics, we constructed algorithm
2H with the following ICD codes: ICD-9 515.x, 516.3, 516.8, 516.9 and ICD-10 J84.1,
J84.89, J84.9. This algorithm had the best Kappa (0.72), specificity (96.8%, 97.3%
relaxed ILD definition), and PPV (69.5%, 75.3% relaxed ILD definition), with minimal
attenuation of sensitivity (80.6%, 74.4% relaxed ILD definition). Algorithm 2H was thus
used for further comparisons in Stage III testing.
Stage III: Provider specialty and diagnostic studies
The additional requirement of a pulmonologist diagnosis (algorithm 3A) increased
the specificity from 96.8% (algorithm 2H) to 98.5%, PPV from 69.5% to 79.9%, and had
substantial agreement by Kappa (0.68; 0.63 relaxed ILD definition) (Table 14). Requiring
a rheumatologist diagnosis (algorithm 3B) modestly improved specificity but reduced
sensitivity and overall algorithm performance by Kappa. Algorithms requiring a CT or
PFTs between 7 and 180 days prior to ILD diagnosis (algorithms 3C and 3D) also
modestly improved specificity and PPV while reducing sensitivity and NPV. Kappa for
these algorithms were 0.72-0.74 (0.69-0.73 relaxed ILD definition). The requirement of a
lung biopsy (algorithm 3E) was highly specific (99.9%) but poorly sensitive (9.3%),
resulting in a PPV of 87.5% and only slight agreement by Kappa (0.15). Requiring a CT,
PFTs, or lung biopsy in addition to a pulmonologist diagnosis (algorithm 3F and 3G)
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modestly affected specificity, PPV, and Kappa. As sensitivity was reduced with the
requirement of a pulmonologist diagnosis (63.7%), we tested an algorithm requiring a
chest CT plus either PFTs or a lung biopsy (algorithm 3H) and an algorithm requiring
either a pulmonologist diagnosis or chest CT plus either PFTs or a lung biopsy
(algorithm 3I). Sensitivity improved in these algorithms to 70.1% and 76.4%. Algorithm
3H had a higher specificity and PPV, but sensitivity and agreement by Kappa were
better for algorithm 3I (Kappa 0.75 vs. 0.73; 0.72 vs. 0.70 sensitive ILD definition).
Algorithm performance for identifying ILD was similar by Kappa between algorithms 3A,
3C, 3D, 3G, 3H, and 3I (0.68-0.75, 0.63-0.72 relaxed ILD definition) indicating
substantial agreement.
Stage IV: Exclusion of other ILD
Using the top-performing models (3A, 3C, 3D, 3G, 3H, 3I), we then excluded
those with a diagnosis code for other causes of ILD that occurred on or after the date of
the last ILD code recorded, following approaches in IPF.129,130,134 After excluding other
causes of ILD, there was modest improvement in specificity and PPV (range 0.7-1.2%
improvement, Table 15) for each algorithm. Specificity for these algorithms ranged from
97.9-98.8%) and PPVs ranged from 76.0-82.9% (80.3-86.6% relaxed ILD definition).
Overall performance by Kappa was similar after excluding other causes of ILD (Kappa
0.67-0.74, 0.61-0.71 relaxed ILD definition). Algorithm 4I had the best agreement with
medical record review (Kappa 0.74, 0.70 relaxed ILD definition), indicating substantial
agreement. Performance metrics for this algorithm were: sensitivity 73.2% (65.4%
relaxed ILD definition), specificity 98.2% (98.5% relaxed ILD definition), and PPV 78.5%
(82.4% relaxed ILD definition).
Sensitivity analyses
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Because ILD may be detected on different types of CT scans (e.g., highresolution, CT-angiogram, or low dose CT for lung cancer screening), we tested both
broad CT codes and specific CT codes. Algorithms performed similarly regardless of the
CT scan codes utilized (Table 16). Similarly, we tested algorithms with specific (open via
thoracotomy and bronchoscopy) and broad (open, bronchoscopy, and percutaneous)
lung biopsy codes. These algorithms also performed similarly, with excellent specificity
but limited sensitivity. We tested algorithms that only required diagnostic testing (CT,
PFT, and lung biopsy) to be completed at least 7 days prior to ILD diagnosis, rather than
within a 7-180 day window. These algorithms had modestly improved sensitivity and
Kappa values. We tested a broader time window for excluding other causes of ILD,
excluding cases if a diagnostic code for other causes of ILD was ever recorded in
national VA data. These algorithms reduced sensitivity and Kappa values. Because
some non-ILD cases had clinical diagnoses or diagnostic testing for ILD but did not fulfill
primary ILD definitions, we compared algorithm 4I against two additional ILD definitions
with fewer requirements. Specificity was ≥98.6% and PPV improved to 83.4% and
86.3% in these models, with Kappa values still suggesting substantial agreement (Kappa
0.67).
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Figure 7. Derivation of study sample and classification of ILD by medical record
review

The Veterans Affairs Rheumatoid Arthritis (VARA) registry was screened for ≥2
outpatient or ≥1 inpatient discharge diagnoses of interstitial lung disease (ILD). Detailed
medical record review was performed for all subjects who screened positive and a
random sample of those who screened negative to validate ILD diagnoses by
abstracting physician diagnoses, imaging findings, pulmonary function tests (PFTs), and
pathology findings. Using the primary stringent ILD definition, 182 cases were identified,
while using a relaxed definition resulted in 203 ILD cases.
Abbreviations: CT, computed tomography; ILD, interstitial lung disease; PFTs,
pulmonary function tests; VARA, Veterans Affairs Rheumatoid Arthritis registry
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Table 11. Characteristics of study cohort at registry enrollment by ILD status
Stringent ILD definition
ILD
No ILD
(n=182)
(n=354)

Relaxed ILD definition
ILD
No ILD
(n=203)
(n=333)

Age, years

66.2 (9.8)

63.6 (10.4)†

66.4 (9.8)

63.4 (10.4)†

Male sex

173 (95.6)

323 (91.2)

193 (95.5)

303 (91.0)

Caucasian

138 (75.8)

273 (77.3)

154 (76.2)

257 (77.2)

Current

53 (29.6)

89 (25.9)

59 (29.8)

83 (25.5)

Former

100 (55.9)

187 (54.4)

109 (55.1)

178 (54.8)

Never

26 (14.5)

68 (19.8)

30 (15.2)

64 (19.7)

High-school education

147 (86.5)

273 (86.7)

161 (85.6)

259 (87.2)

RA duration, years

11.7 (12.6)

11.1 (11.1)

12.0 (12.7)

10.9 (10.9)

Anti-CCP antibody +

137 (83.0)

246 (80.4)

152 (83.5)

231 (79.9)

Rheumatoid factor +

144 (87.8)

243 (79.2)†

158 (87.3)

229 (79.0)†

DAS28

4.2 (1.4)

4.0 (1.6)

4.2 (1.4)

4.0 (1.6)

MDHAQ

1.0 (0.6)

1.0 (0.6)

1.0 (0.6)

1.0 (0.6)

Methotrexate

51 (30.7)

163 (52.2)†

59 (32.1)

155 (52.7)†

bDMARDs

52 (28.6)

79 (22.3)

56 (27.6)

75 (22.5)

Prednisone

103 (62.1)

123 (39.4)†

113 (61.4)

113 (38.4)†

Patient Characteristics

Smoking status

Interstitial Lung Disease Status (by medical record review)
Screened positive for ILD

177 (97.3)

116 (32.8)†

196 (96.6)

97 (29.1)†

Pulmonologist diagnosis

172 (94.5)

5 (1.4)†

172 (84.7)

5 (1.5)†

Non-pulmonologist diagnosis

175 (96.2)

30 (8.5)†

196 (96.6)

9 (2.7)†

Imaging consistent with ILD

182 (100.0)

48 (13.6)†

202 (99.5)

28 (8.4)†

CT evidence of ILD

179 (98.4)

40 (11.3)†

195 (96.1)

24 (7.2)†

Restrictive pattern on PFTs

98 (53.9)

35 (9.9)†

99 (48.8)

34 (10.2)†

Pathology suggesting ILD

22 (12.1)

3 (0.9)†

23 (11.3)

2 (0.6)†

Prevalent at enrollment

91 (50.0)

-

101 (49.8)

-

Values mean (SD) or n (%) of non-missing, † P < 0.05 by independent t-test or chi-square test
Abbreviations: anti-CCP, anti-cyclic citrullinated peptide antibody; bDMARDs, biologic diseasemodifying anti-rheumatic drugs; CT, computed tomography; DAS28, 28-joint disease activity
score; MDHAQ, multidimensional health assessment questionnaire; ILD, interstitial lung
disease; PFTs, pulmonary function tests; RA, rheumatoid arthritis; SD, standard deviation
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Table 12. Performance of RA-ILD algorithms with various encounter type and diagnostic code frequency (Stage I)
Algorithm

Descriptiona

Stringent ILD definition
1A

≥1 outpatient diagnosis

1B

≥1 discharge diagnosis

1C
1D
1E
1F

≥1 outpatient or discharge
diagnosis
≥2 outpatient diagnosis, >30
days apart
≥1 discharge diagnosis or ≥2
outpatient diagnosis, >30 days
apart
≥2 diagnosesb, >30 days apart

≥2 diagnosesb, >30 days and
≤365 days apart
≥2 diagnosesb, >30 days and
1H
≤730 days apart
Relaxed ILD definition
1G

1A

≥1 outpatient diagnosis

1B

≥1 discharge diagnosis

1C
1D

≥1 outpatient or discharge
diagnosis
≥2 outpatient diagnosis, >30
days apart

Sensitivity

Specificity

PPV

NPV

%Agreement

85.8
(68.8, 94.3)
48.4
(38.9, 58.0)
87.3
(68.9, 95.6)

91.2
(89.9, 92.4)
96.9
(96.3, 97.3)
89.8
(88.6, 91.0)

48.2
(40.1, 56.3)
58.9
(52.4, 65.2)
44.7
(37.7, 52.0)

98.5
(96.1, 99.5)
95.3
(93.2, 96.7)
98.7
(96.0, 99.6)

80.7
(65.7, 90.1)

96.5
(95.6, 97.3)

68.2
(59.6, 75.7)

98.2
(96.1, 99.2)

95.2

0.71
(0.62, 0.79)

85.2
(67.8, 94.0)

94.5
(93.4, 95.4)

58.7
(51.0, 66.0)

98.6
(96.2, 99.5)

93.7

0.66
(0.58, 0.74)

81.7
(66.4, 91.0)
66.3
(55.0, 76.1)

96.0
(95.0, 96.8)
97.0
(96.2, 97.7)

65.5
(56.9, 73.3)
67.0
(58.0, 74.9)

98.3
(96.1, 99.2)
96.9
(95.2, 98.1)

72.1
(59.6, 81.9)

96.8
(95.9, 97.5)

67.2
(58.2, 75.1)

97.4
(95.6, 98.5)

87.3
(72.5, 94.7)
44.8
(36.1, 53.7)
89.3
(72.7, 96.3)

92.8
(91.0, 94.2)
97.2
(96.7, 97.6)
91.4
(89.7, 92.8)

58.1
(47.9, 67.6)
63.8
(57.4, 69.7)
53.8
(45.0, 62.4)

98.4
(96.1, 99.4)
94.1
(91.6, 95.8)
98.7
(96.0, 99.6)

91.9

74.6
(60.5, 84.9)

97.1
(96.1, 97.8)

73.9
(65.3, 81.0)

97.2
(94.7, 98.5)

94.9

90.8
92.7
89.6

94.8
94.5
94.7

92.2

91.1

Kappa
0.57
(0.48, 0.65)
0.49
(0.41, 0.57)
0.54
(0.46, 0.52)

0.70
(0.61, 0.78)
0.64
(0.55, 0.72)
0.67
(0.58, 0.75)
0.65
(0.56, 0.74)
0.48
(0.41, 0.56)
0.62
(0.53, 0.71)
0.71
(0.62, 0.79)
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1E

≥1 discharge diagnosis or ≥2
outpatient diagnosis, >30 days
apart

1F

≥2 diagnosesb, >30 days apart

1G
1H

≥2 diagnosesb, >30 days and
≤365 days apart
≥2 diagnosesb, >30 days and
≤730 days apart

80.0
(63.8, 90.0)

95.2
(94.1, 96.1)

64.6
(56.9, 71.6)

97.7
(95.0, 99.0)

76.3
(61.8, 86.5)
62.7
(51.4, 72.7)

96.7
(95.6, 97.5)
97.6
(96.8, 98.3)

71.6
(63.0, 78.9)
74.3
(65.4, 81.6)

97.4
(94.8, 98.7)
96.0
(93.8, 97.5)

68.0
(55.6, 78.2)

97.4
(96.5, 98.1)

74.4
(65.4, 81.7)

96.5
(94.2, 97.9)

93.7
94.6
94.2
94.5

0.68
(0.59, 0.76)
0.71
(0.61, 0.79)
0.65
(0.56, 0.73)
0.68
(0.59, 0.76)

ICD-9: 515.x, 516.3, 516.8, 516.9, 714.81; ICD-10: M05.1x, J84.1, J84.2, J84.89, J84.9, J99
outpatient or discharge diagnoses
Abbreviations: PPV, positive predictive value; NPV, negative predictive value; ILD, interstitial lung disease; CT, computed tomography; PFT,
pulmonary function test
a
b
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Table 13. Performance of RA-ILD algorithms with various ILD diagnostic codes (Stage II)
Algorithm

Description

Stringent ILD definition
2A

All ILD codes*

Exclude M05.1x
(n=6 excluded)
Exclude J84.2
2C
(n=0 excluded)
Exclude J84.89 & J84.9
2D
(n=3 excluded)
Exclude J99
2E
(n=0 excluded)
Exclude 714.81
2F
(n=8 excluded)
Exclude 516.8, 516.9
2G
(n=31 excluded)
ICD-9 515.x, 516.3, 516.8, 516.9;
2H
ICD-10 J84.1, J84.89, J84.9
(n=17 excluded)
Relaxed ILD definition
2B

2A
2B
2C
2D

All ILD codes*
Exclude M05.1x
(n=6 excluded)
Exclude J84.2
(n=0 excluded)
Exclude J84.89 & J84.9
(n=3 excluded)

Sensitivity

Specificity

PPV

NPV

%Agreement

81.7
(66.4, 91.0)
81.0
(65.7, 90.5)

96.0
(95.0, 96.8)
96.3
(95.4, 97.1)

65.5
(56.9, 73.3)
67.0
(58.9, 74.2)

98.3
(96.1, 99.2)
98.2
(96.1, 99.2)

81.7
(66.4, 91.0)

96.0
(95.0, 96.8)

65.5
(56.9, 73.3)

98.3
(96.1, 99.2)

94.8

0.70
(0.61, 0.78)

76.9
(61.2, 87.5)

96.2
(95.3, 96.8)

64.9
(57.4, 71.7)

97.8
(95.5, 99.0)

94.5

0.67
(0.59, 0.75)

81.7
(66.4, 91.0)

96.0
(95.0, 96.8)

65.5
(56.9, 73.3)

98.3
(96.1, 99.2)

94.8

0.70
(0.61, 0.78)

81.3
(66.1, 90.6)

96.3
(95.3, 97.1)

67.1
(58.3, 74.9)

98.2
(96.1, 99.2)

95.0

0.71
(0.62, 0.78)

74.6
(61.6, 84.3)

96.6
(95.6, 97.4)

67.3
(57.8, 75.5)

97.6
(95.7, 98.7)

94.8

0.68
(0.59, 0.76)

80.6
(65.5, 90.1)

96.8
(95.8, 97.5)

69.5
(61.1, 76.7)

98.2
(96.1, 99.2)

95.4

0.72
(0.63, 0.80)

76.3
(61.8, 86.5)
75.2
(60.9, 85.5)

96.7
(95.6, 97.5)
97.0
(96.0, 97.7)

71.6
(63.0, 78.9)
72.9
(64.9, 79.7)

97.4
(94.8, 98.7)
97.3
(94.8, 98.6)

76.3
(61.8, 86.5)

96.7
(95.6, 97.5)

71.6
(63.0, 78.9)

97.4
(94.8, 98.7)

94.6

0.71
(0.61, 0.79)

72.1
(57.7, 83.1)

96.8
(96.0, 97.5)

71.3
(63.9, 77.7)

96.9
(94.2, 98.4)

94.4

0.69
(0.59, 0.77)

94.8
95.1

94.6
94.8

Kappa
0.70
(0.61, 0.78)
0.71
(0.62, 0.78)

0.71
(0.61, 0.79)
0.71
(0.62, 0.79)
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2E
2F
2G
2H

Exclude J99
(n=0 excluded)
Exclude 714.81
(n=8 excluded)
Exclude 516.8, 516.9
(n=31 excluded)
ICD-9 515.x, 516.3, 516.8, 516.9;
ICD-10 J84.1, J84.89, J84.9
(n=17 excluded)

76.3
(61.8, 86.5)

96.7
(95.6, 97.5)

71.6
(63.0, 78.9)

97.4
(94.8, 98.7)

94.6

0.71
(0.61, 0.79)

75.5
(61.2, 85.8)

96.9
(95.9, 97.7)

73.0
(64.1, 80.3)

97.3
(94.8, 98.6)

94.8

0.71
(0.62, 0.79)

68.3
(56.0, 78.5)

97.1
(96.0, 97.8)

72.1
(62.5, 80.0)

96.5
(94.2, 97.9)

94.2

0.67
(0.57, 0.75)

74.4
(60.3, 84.8)

97.3
(96.4, 98.0)

75.3
(67.0, 82.1)

97.2
(94.7, 98.5)

95.1

0.72
(0.63, 0.80)

*ICD-9: 515.x, 516.3, 516.8, 516.9, 714.81; ICD-10: M05.1x, J84.1, J84.2, J84.89, J84.9, J99
Abbreviations: PPV, positive predictive value; NPV, negative predictive value; ILD, interstitial lung disease; CT, computed tomography; PFT,
pulmonary function test
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Table 14. Performance of RA-ILD algorithms with various provider specialties and diagnostic testing (Stage III)
Algorithm

Description*

Stringent ILD definition
3A

≥1 pulmonologist ILD diagnosis

3B

≥1 rheumatologist ILD diagnosis

CT 7-180 days prior to ILD
diagnosis
PFT 7-180 days prior to ILD
3D
diagnosis
Lung biopsy 7-180 days prior to
3E
ILD diagnosis
≥1 pulmonologist diagnosis and
3F
CT or lung biopsy 7-180 days prior
to ILD diagnosis
≥1 pulmonologist diagnosis and
3G
CT or lung biopsy or PFTs 7-180
days prior to ILD diagnosis
CT and PFTs or lung biopsy 7-180
3H
days prior to ILD diagnosis
Pulmonologist diagnosis or CT and
3I
PFTs or lung biopsy 7-180 days
prior to ILD diagnosis
Relaxed ILD definition
3C

3A

≥1 pulmonologist ILD diagnosis

3B

≥1 rheumatologist ILD diagnosis

Sensitivity

Specificity

PPV

NPV

%Agreement

63.7
(51.8, 74.1)
55.7
(45.3, 65.5)
72.9
(58.8, 83.5)

98.5
(97.7, 99.0)
98.0
(97.3, 98.5)
97.7
(96.8, 98.4)

79.9
(69.8, 87.2)
72.1
(62.9, 79.7)
75.2
(65.3, 83.0)

96.7
(94.7, 97.9)
96.0
(94.1, 97.3)
97.5
(95.3, 98.6)

94.4

75.0
(62.1, 84.6)

98.1
(97.5, 98.5)

78.1
(72.2, 83.1)

97.7
(95.8, 98.7)

96.1

0.74
(0.66, 0.81)

9.3
(7.3, 11.8)

99.9
(99.6, 99.9)

87.5
(67.6, 95.9)

92.2
(90.3, 93.7)

92.1

0.15
(0.12, 0.20)

58.2
(46.7, 68.9)

98.4
(98.0, 98.7)

77.5
(72.0, 82.2)

96.2
(94.0, 97.6)

95.0

0.64
(0.55, 0.72)

63.0
(51.3, 73.4)

98.6
(97.9, 99.1)

81.0
(71.5, 87.9)

96.6
(94.6, 97.9)

95.6

0.69
(0.59, 0.77)

70.1
(57.3, 80.4)

98.5
(98.0, 98.9)

81.9
(76.0, 86.6)

97.2
(95.1, 98.4)

96.0

0.73
(0.64, 0.81)

76.4
(62.7, 86.2)

98.0
(97.2, 98.5)

77.4
(69.1, 84.0)

97.9
(96.0, 98.9)

96.2

0.75
(0.66, 0.82)

55.5
(45.1, 65.4)
52.5
(42.7, 62.1)

98.6
(97.8, 99.1)
98.5
(97.8, 99.0)

81.6
(71.5, 88.6)
79.7
(70.7, 86.4)

95.2
(92.9, 96.8)
95.0
(92.7, 96.6)

95.5

95.6

94.3
94.0

Kappa
0.68
(0.59, 0.77)
0.60
(0.51, 0.68)
0.72
(0.62, 0.80)

0.63
(0.53, 0.72)
0.60
(0.51, 0.69)
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3C
3D
3E
3F

3G
3H
3I

CT 7-180 days prior to ILD
diagnosis
PFT 7-180 days prior to ILD
diagnosis
Lung biopsy ≥7 days prior to ILD
diagnosis
≥1 pulmonologist diagnosis and
CT or lung biopsy 7-180 days prior
to ILD diagnosis
≥1 pulmonologist diagnosis and
CT or lung biopsy or PFTs 7-180
days prior to ILD diagnosis
CT and PFTs or lung biopsy 7-180
days prior to ILD diagnosis
Pulmonologist diagnosis or CT and
PFTs or lung biopsy 7-180 days
prior to ILD diagnosis

65.8
(53.2, 76.4)

98.1
(97.1, 98.7)

79.3
(69.4, 86.7)

96.2
(93.8, 97.8)

94.8

0.69
(0.59, 0.78)

68.2
(56.1, 78.3)

98.5
(98.0, 98.9)

83.3
(77.7, 87.6)

96.6
(94.3, 98.0)

95.5

0.73
(0.64, 0.80)

8.3
(6.7, 10.4)

99.9
(99.7, 99.9)

91.7
(72.1, 97.9)

90.8
(88.6, 92.6)

90.8

0.14
(0.11, 0.18)

50.9
(41.1, 60.6)

98.5
(98.1, 98.8)

79.3
(74.0, 83.7)

94.8
(92.3, 96.5)

93.8

0.59
(0.50, 0.67)

55.0
(44.7, 64.8)

98.7
(98.0, 99.2)

82.8
(73.2, 89.4)

95.2
(92.9, 96.8)

94.4

0.63
(0.54, 0.72)

62.8
(51.4, 72.9)

98.8
(98.3, 99.1)

85.4
(79.9, 89.7)

95.9
(93.5, 97.4)

95.1

0.70
(0.61, 0.78)

68.2
(55.8, 78.4)

98.3
(97.5, 98.8)

81.0
(72.8, 87.2)

96.6
(94.3, 98.0)

95.3

0.72
(0.62, 0.79)

*ICD-9: 515.x, 516.3, 516.8, 516.9; ICD-10: J84.1, J84.89, J84.9
Abbreviations: PPV, positive predictive value; NPV, negative predictive value; ILD, interstitial lung disease; CT, computed tomography; PFT,
pulmonary function test
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Table 15. Performance of RA-ILD algorithms with exclusion of other ILD (Stage IV)
Algorithm

Description

Stringent ILD definition
≥1 pulmonologist ILD diagnosis and
4A
exclusion other ILDa
CT 7-180 days prior to ILD
4C
diagnosis and exclusion other ILDa
PFT 7-180 days prior to ILD
4D
diagnosis and exclusion other ILDa
≥1 pulmonologist diagnosis and CT
or lung biopsy or PFTs 7-180 days
4G
prior to ILD diagnosis and exclusion
other ILDa
CT and PFTs or lung biopsy 7-180
4H
days prior to ILD diagnosis and
exclusion other ILDa
Pulmonologist diagnosis or CT and
PFTs or lung biopsy 7-180 days
4I
prior to ILD diagnosis and exclusion
other ILDa
Relaxed ILD definition
≥1 pulmonologist ILD diagnosis and
4A
exclusion other ILDa
CT 7-180 days prior to ILD
4C
diagnosis and exclusion other ILDa
PFT 7-180 days prior to ILD
4D
diagnosis and exclusion other ILDa

Sensitivity

Specificity

PPV

NPV

%Agreement

Kappa

60.4
(49.2, 70.7)

98.7
(97.9, 99.2)

81.1
(70.8, 88.4)

96.4
(94.4, 97.7)

95.4

0.67
(0.57, 0.75)

69.7
(56.5, 80.4)

97.9
(97.0, 98.6)

76.0
(65.9, 83.8)

97.2
(95.1, 98.4)

95.5

0.70
(0.60, 0.79)

71.7
(59.6, 81.4)

98.2
(97.7, 98.6)

78.8
(72.7, 83.8)

97.4
(95.6, 98.5)

96.0

0.73
(0.65, 0.80)

59.8
(48.7, 70.0)

98.8
(98.1, 99.2)

81.9
(72.2, 88.7)

96.4
(94.4, 97.7)

95.5

0.67
(0.57, 0.75)

66.9
(54.9, 77.1)

98.7
(98.2, 99.0)

82.9
(76.9, 87.6)

96.9
(94.8, 98.1)

95.9

0.72
(0.63, 0.79)

73.2
(60.3, 83.0)

98.2
(97.4, 98.7)

78.5
(70.1, 85.1)

97.6
(95.7, 98.6)

96.1

0.74
(0.65, 0.81)

52.8
(42.9, 62.4)

98.8
(98.0, 99.3)

82.9
(72.6, 90.0)

95.0
(92.7, 96.6)

94.2

0.62
(0.52, 0.70)

63.0
(51.1, 73.6)

98.3
(97.3, 98.9)

80.3
(70.1, 87.6)

96.0
(93.5, 97.5)

94.7

0.68
(0.58, 0.77)

65.4
(53.9, 75.4)

98.7
(98.2, 99.0)

84.2
(78.6, 88.6)

96.3
(94.1, 97.7)

95.4

0.71
(0.62, 0.79)
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4G

4H

4I
a exclusion

≥1 pulmonologist diagnosis and CT
or lung biopsy or PFTs 7-180 days
prior to ILD diagnosis and exclusion
other ILDa
CT and PFTs or lung biopsy 7-180
days prior to ILD diagnosis and
exclusion other ILDa
Pulmonologist diagnosis or CT and
PFTs or lung biopsy 7-180 days
prior to ILD diagnosis and exclusion
other ILDa

52.2
(42.5, 61.7)

98.9
(98.2, 99.3)

83.7
(74.1, 90.3)

95.0
(92.7, 96.6)

94.3

0.61
(0.52, 0.70)

60.0
(49.2, 70.0)

98.9
(98.5, 99.3)

86.6
(81.0, 90.8)

95.6
(93.2, 97.2)

95.0

0.68
(0.59, 0.76)

65.4
(53.6, 75.5)

98.5
(97.7, 99.0)

82.4
(74.0, 88.5)

96.3
(94.1, 97.7)

95.2

0.70
(0.61, 0.78)

of other ILD using diagnostic codes for pneumoconioses, radiation, hypersensitivity pneumonitis, other connective tissue diseases
on or after the last ILD diagnosis code date (see Appendix F)
Abbreviations: PPV, positive predictive value; NPV, negative predictive value; ILD, interstitial lung disease; CT, computed tomography; PFT,
pulmonary function test
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Table 16. Performance of modified RA-ILD algorithms (sensitivity analyses)
Algorithm

Description/modificationa

Stringent ILD definition
3C

CT ≥7 days prior to ILD diagnosis

3C

CT ≥7 days prior to ILD diagnosis
with broad codesb

3D

PFT ≥7 days prior to ILD diagnosis

Lung biopsy ≥7 days prior to ILD
diagnosis
Lung biopsy ≥7 days prior to ILD
3E
diagnosis with broad codes
≥1 pulmonologist diagnosis and CT
3F
or lung biopsy ≥7 days prior to ILD
diagnosis
≥1 pulmonologist diagnosis and CT
3G
or lung biopsy or PFTs ≥7 days prior
to ILD diagnosis
Pulmonologist diagnosis or CT and
PFTs or lung biopsy 7-180 days
4I
prior to ILD diagnosis and exclusion
other ILD ever
Relaxed ILD definition
3E

3C
3C
3D

CT ≥7 days prior to ILD diagnosis
CT ≥7 days prior to ILD diagnosis
with broad codesb
PFT ≥7 days prior to ILD diagnosis

Sensitivity

Specificity

PPV

NPV

%Agreement

78.1
(63.8, 87.9)
78.2
(63.9, 87.9)
80.0
(66.2, 89.1)
11.5
(9.2, 14.4)

97.2
(96.4, 97.9)
97.2
(96.3, 97.8)
97.5
(96.9, 97.9)
99.9
(99.6, 99.9)

72.0
(63.6, 79.0)
71.6
(63.1, 78.7)
75.4
(69.8, 80.3)
89.7
(72.4, 96.6)

98.0
(96.0, 99.0)
98.0
(96.1, 99.0)
98.0
(96.0, 99.0)
92.4
(90.5, 93.9)

12.4
(9.8, 15.7)

99.8
(99.5, 99.9)

84.8
(68.4, 93.5)

92.4
(90.5, 94.0)

92.3

0.20
(0.16, 0.25)

62.8
(51.1, 73.1)

98.5
(97.7, 99.0)

79.7
(69.5, 87.1)

96.6
(94.6, 97.9)

95.5

0.68
(0.58, 0.76)

63.2
(51.4, 73.6)

98.5
(97.7, 99.0)

79.8
(69.7, 87.1)

96.6
(94.6, 97.9)

95.5

0.68
(0.58, 0.77)

68.5
(56.8, 78.3)

98.4
(97.6, 98.9)

79.1
(70.4, 85.8)

97.2
(95.4, 98.3)

95.9

0.71
(0.62, 0.79)

70.8
(57.7, 81.2)
70.9
(57.7, 81.2)

97.6
(96.8, 98.3)
97.6
(96.7, 98.2)

76.6
(68.3, 83.2)
76.1
(67.8, 82.9)

96.9
(94.5, 98.2)
96.9
(94.5, 98.2)

73.9

98.0

81.0

97.0

95.6
95.6
95.9
92.3

95.0
95.0
95.5

Kappa
0.73
(0.64, 0.80)
0.72
(0.63, 0.80)
0.75
(0.68, 0.82)
0.19
(0.15, 0.24)

0.71
(0.61, 0.79)
0.71
(0.61, 0.79)
0.75
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(60.8, 83.7)

(97.5, 98.5)

(75.8, 85.4)

Lung biopsy ≥7 days prior to ILD
10.2
99.9
93.1
3E
(8.2, 12.7) (99.7, 99.9) (76.2, 98.3)
diagnosis
Lung biopsy ≥7 days prior to ILD
11.0
99.8
87.9
3E
(8.8, 13.7) (99.6, 99.9) (71.8, 95.4)
diagnosis with broad codes
≥1 pulmonologist diagnosis and CT
54.8
98.6
81.4
3F
or lung biopsy ≥7 days prior to ILD
(44.5, 64.6) (97.8, 99.1) (71.2, 88.5)
diagnosis
≥1 pulmonologist diagnosis and CT
55.1
98.6
81.5
3G
or lung biopsy or PFTs ≥7 days prior
(44.8, 65.0) (97.8, 99.1) (71.3, 88.6)
to ILD diagnosis
Pulmonologist diagnosis or CT and
PFTs or lung biopsy 7-180 days
61.4
98.7
83.3
4I
(50.5, 71.3) (97.9, 99.1) (74.6, 89.5)
prior to ILD diagnosis and exclusion
c
other ILD ever
Two of clinical diagnosis of ILD, CT, restrictive PFTs, or biopsy (n=210 ILD)
Pulmonologist diagnosis or CT and
PFTs or lung biopsy 7-180 days
60.5
98.6
83.4
4I
(49.1, 70.8) (97.8, 99.1) (75.0, 89.4)
prior to ILD diagnosis and exclusion
other ILDc
Clinical diagnosis of ILD or two of CT, restrictive PFTs, or biopsy (n=220 ILD)
Pulmonologist diagnosis or CT and
PFTs or lung biopsy 7-180 days
58.7
98.8
86.3
4I
(47.8, 68.8) (98.0, 99.3) (0.78, 0.92)
prior to ILD diagnosis and exclusion
other ILDc
a ICD-9:

(94.6, 98.4)
90.9
(88.8, 92.7)

91.0

(0.66, 0.82)
0.17
(0.13, 0.21)

91.0
(88.8, 92.8)

91.0

0.18
(0.14, 0.22)

95.2
(92.9, 96.8)

94.2

0.62
(0.53, 0.71)

95.2
(92.9, 96.8)

94.3

0.63
(0.53, 0.72)

95.9
(93.7, 97.4)

95.0

0.68
(0.59, 0.76)

95.4
(92.8, 97.1)

94.5

0.67
(0.57, 0.76)

94.9
(92.2, 96.7)

94.2

0.67
(0.57, 0.75)

515.x, 516.3, 516.8, 516.9; ICD-10: J84.1, J84.89, J84.9; b broad CT codes (includes CT-A and low dose CT); c Excluding when
diagnostic codes for pneumoconioses, radiation, hypersensitivity pneumonitis, or other connective tissue diseases were present (Appendix F)
Abbreviations: PPV, positive predictive value; NPV, negative predictive value; ILD, interstitial lung disease; CT, computed tomography; PFT,
pulmonary function test
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4.4

Discussion
To facilitate the use of administrative data for RA-ILD research, we have

characterized the performance of administrative algorithms for identifying ILD among RA
patients compared to detailed medical record review. Algorithms including specific ICD-9
and ICD-10 ILD codes attributed to multiple encounters, pulmonologist diagnosis or
diagnostic testing, and exclusion of other causes of ILD were able to accurately classify
ILD. The best performing algorithm (algorithm 4I, Table 15) requiring ≥2 ILD diagnosis
codes at least 30 days apart, a single pulmonologist diagnosis for ILD or CT and either
PFTs or lung biopsy 7-180 days prior to ILD diagnosis, and exclusion of other ILD
causes after the last ILD diagnosis yielded substantial agreement to medical record
review by Kappa (0.74). PPVs for this algorithm ranged from 78.5-86.3% depending on
the requirements of the ILD reference-standard definition. Because there is a trade-off
between sensitivity and specificity with these ILD algorithms and differences in
availability of algorithm components within different datasets, the choice of algorithm will
depend on the purpose of the study and available data. Our results provide detailed data
on the performance of several ILD algorithms that will support investigator selection of
ILD case finding approaches in future studies.
Similar to administrative algorithms developed to identify RA80 and other
rheumatic conditions,81-83 the requirement of multiple diagnosis codes for ILD separated
over time enhanced the specificity and PPV of administrative ILD algorithms.
Importantly, these results demonstrate that some diagnosis codes incorporated into prior
RA-ILD algorithms lack specificity for ILD.63,77,78,84,125 Most notably among these were
ICD-9 (714.81) and ICD-10 (M05.1x) codes for “rheumatoid lung”. Because there are
numerous pulmonary manifestations of RA including ILD, obstructive lung disease,
nodules, and pleural effusions,44 these codes may be used for these other entities in the
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setting of RA. Indeed, pleural effusions and pulmonary nodules were reasons for these
codes occurring in the absence of ILD. We recommend the following ICD-9 and ICD-10
codes for identifying ILD in RA patients: ICD-9 515.x, 516.3, 516.8 and ICD-10 J84.1,
J84.89, J84.9 (bolded in Appendix D).
Our results illustrate that requiring a pulmonologist diagnosis of ILD achieves
excellent specificity (algorithm 3A, 98.5%), but at the expense of sensitivity (63.7%). This
reduction in sensitivity may be exaggerated in our cohort because pulmonologist
diagnoses outside the VA health care system would not be captured by our algorithms.
Therefore, algorithms with pulmonologist diagnosis may actually perform better in other
settings. At least in our sample, requiring further diagnostic testing such as chest CT,
PFTs, and lung biopsy did not significantly improve the PPV or Kappa from algorithms
that already included a pulmonologist diagnosis of ILD. Eliminating the requirement of a
pulmonologist diagnosis, we found that requiring a recent CT plus PFTs or lung biopsy in
the prior 6 months achieved a similar PPV (81.9% vs. 79.9%). Using broad vs. specific
CPT codes for these diagnostic tests rendered little impact on model performance.
Combining either a pulmonologist diagnosis or the aforementioned diagnostic tests
(algorithm 3I) optimized the sensitivity while preserving a reasonable specificity, leading
to optimal algorithm performance by Kappa. Further refining this algorithm with exclusion
of other ILD causes maintained overall algorithm performance while modestly increasing
PPV (algorithm 4I).
Because we performed detailed medical record review on a random sample of
VARA participants who did not screen positive for ILD, we were able to assess not only
the specificity and PPV but also the sensitivity and NPV. Algorithms that incorporated
pulmonologist diagnosis or diagnostic testing obtained the highest PPV (≥78.5%), but
algorithms without these additional criteria had similar Kappa values (0.72), reflecting
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improvements in specificity at the expense of sensitivity. As the overall performance
(measured by Kappa) did not significantly differ for several algorithms, choice should be
directed by specific study needs for either greater sensitivity or specificity and data
availability. For example, completion of RA-ILD comparative effectiveness and outcomes
research in large administrative datasets will require specific ILD algorithms, such as
algorithm 4I (PPV 78.5-86.3%). Epidemiologic studies of RA-ILD, rather, may implement
both a specific (algorithm 4I) and more sensitive algorithm (algorithm 2H, NPV 98.2%
and 97.9%), recognizing the “truth” lies between the estimates from the specific and
sensitive algorithms.
The generalizability of our findings may be limited by male predominance of the
VARA registry, unique exposures of the Veteran population, as well as the coding
practices represented by the 13 VARA-associated VA medical centers at which this work
was conducted. However, the Veterans Health Administration represents the largest
integrated health care system in the US with reduced barriers to access among its
beneficiaries and a single electronic health record. Patients may receive care outside the
VA, which affects capture by administrative algorithms and medical record review. To
mitigate this, we reviewed the clinical notes for mention of outside care and selected
claims originating from non-VA care when constructing our administrative ILD
algorithms. Supporting the validity of our findings is that limited testing in a prior study of
Kaiser Permanente Northern California found a PPV of 63% for ≥2 ILD diagnosis codes
using imaging reports for ILD validation.126 This is in agreement with the PPV of 65.5%
for a similar algorithm (algorithm 1F) in our study. The derived ILD algorithms are also
currently being externally validated in additional non-VA datasets.
Validation of ILD diagnoses through medical records was retrospective, with
diagnostic testing dictated through regular clinical care and interpreted by the treating
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providers. Additionally, there are currently no widely accepted classification criteria for
RA-ILD. Because of the potential of misclassification in our reference standard, we used
stringent and relaxed primary ILD definitions for each stage of algorithm development
and testing. Furthermore, because some participants who did not fulfill the stringent or
relaxed primary ILD definitions had clinical diagnoses or diagnostic testing suggestive of
ILD, we performed sensitivity analyses comparing optimal algorithms to ILD definitions
with fewer requirements. Overall algorithm performance was consistent between ILD
definitions, with increased PPV using ILD definitions with fewer requirements. Because
only approximately 10% of ILD cases were initially diagnosed after ICD-10
implementation, our findings may underestimate ICD-10 code contribution to ILD
classification, a possibility that will need to be addressed in future research. Finally, we
assessed the accuracy of ILD algorithms within a cohort fulfilling 1987 ACR criteria,93
and the performance of these algorithms may vary if applied outside of this setting (e.g.,
in combination with administrative algorithms to identify RA). However, the results from
our study will serve as a valuable benchmark for future efforts focused on external
validation. Given the high specificity of administrative algorithms for RA,80 we would
anticipate to observe minimal reductions in the specificity of these ILD algorithms.
In conclusion, we have demonstrated that administrative algorithms can be used
to accurately identify ILD in a RA cohort. Our results detail the performance metrics of
these different algorithms for ILD, which can be applied to large administrative data
sources to perform further clinical and epidemiologic study of RA-ILD.
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CHAPTER 5: DISCUSSION
5.1

Summary
RA causes significant morbidity and mortality, with respiratory-related deaths

being the most overrepresented cause of death in RA.26,27 In this dissertation,
investigation into the prognosis of chronic lung diseases in RA was assessed and
compared to cardiovascular disease. Subsequently, a novel serum biomarker for the
most fatal RA-associated lung disease, RA-ILD, was evaluated. Finally, accurate
algorithms for classifying RA-ILD in large, real-world datasets were derived. With these
results, we now have biological and biomedical informatics tools to more optimally
investigate RA-associated lung diseases and enhance its identification.
The importance of considering, studying, and managing chronic lung disease in
RA was illustrated by our findings in Chapter 2 that comorbid lung disease carried a
prognosis as poor as cardiovascular disease in patients with RA. The risk of death was
1.5-fold higher in RA subjects with comorbid chronic lung disease and 1.6-fold higher in
RA subjects with cardiovascular disease compared to RA subjects with neither
comorbidity. This poor prognosis was not limited to RA-ILD but also present for COPD,
bronchiectasis, and other lower respiratory diseases. We also confirmed that RA-ILD
carried the greatest mortality risk among the RA-associated lung diseases. Challenging
the common therapeutic dogma that methotrexate should be avoided in RA patients with
chronic lung disease, we did not find a higher risk of death in RA patients with lung
disease receiving methotrexate than RA patients without lung disease.
In Chapter 3, we tested the hypothesis that higher serum concentrations of antiMAA antibody would be significantly associated with RA-ILD independent of established
RA-ILD risk factors. Consistent with our hypothesis, IgA and IgM anti-MAA antibody
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isotype concentrations in the upper three quartiles were associated with a more than 2fold higher odds of ILD among our RA population. Moreover, we assembled a diseased
control group, demonstrating that anti-MAA antibody (specifically the IgM isotype) is
uniquely higher in ILD than RA patients with COPD (a chronic condition also more
common in RA with overlapping manifestations). Beyond the potential role of anti-MAA
antibody as a specific serum biomarker of RA-ILD based on these results, our
investigation of lung tissues from RA-ILD subjects and controls (diseased and healthy)
demonstrated the enhanced presence of MAA-modified proteins in the lungs from RAILD subjects. In RA-ILD, MAA modified proteins co-localized with other RA autoantigens
(citrulline), relevant immune effector cells, and extracellular matrix proteins. These
findings implicate MAA and immune responses to MAA in the pathogenesis of RA-ILD.
Finally, to enable much needed comparative effectiveness and outcomes
research in RA-ILD we leveraged a large RA registry and linkage to national
administrative data to develop algorithms for RA-ILD as part of efforts outlined in
Chapter 4. Administrative based algorithms for RA-ILD with multiple ILD diagnostic
codes plus either a pulmonologist diagnosis of ILD or testing for ILD (CT, PFTs, or lung
biopsy) achieved >98% specificity and had substantial agreement with the reference
standard of medical record review. With the understanding that varying the components
of a proposed ILD algorithm would naturally result in a trade-off between sensitivity and
specificity, we provided detailed performance characteristics for several different RA-ILD
algorithms that could serve as a resource for different types of clinical and epidemiologic
research in RA-ILD using a variety of data sources.
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5.2

Future work
Serum biomarkers hold substantial promise for case-finding approaches,

including their integration into ILD screening protocols that could be widely deployed in
patients with RA. In this situation, sensitivity is the diagnostic characteristic of the
biomarker (or screening protocol) that is most critical. A highly sensitive biomarker could
provide for efficient case finding, identifying high-risk patients that would benefit from
additional, more resource-intensive testing needed to confirm the diagnosis. In contrast,
if a biomarker is highly specific for RA-ILD, confirmatory testing with a high-resolution CT
and PFTs are likely to still be needed as these tests provide information that will
ultimately guide treatment selection and predict prognosis. Findings on CT may suggest
the histopathologic pattern of RA-ILD that has implications for treatment selection with
the belief that anti-fibrotic therapies have more efficacy in usual interstitial pneumonia
(as in IPF with its typical “honeycombing” appearance on CT) while immunomodulatory
therapies have greater efficacy in non-specific interstitial pneumonia (with its typical CT
findings of “ground glass” and absence of “honeycombing”). The degree of lung
involvement on CT and physiologic impairment on PFTs provide prognostic information
to providers and patients.135-137 Furthermore, the results of these tests will serve as
baseline values that will be followed longitudinally to determine if treatments are effective
or if the underlying disease is progressing.138,139
In Chapter 3, we showed that anti-MAA antibody was independently associated
with RA-ILD. In contrast, patients with RA and the lowest values of anti-MAA antibody
were substantially less likely to have ILD, suggesting anti-MAA antibody could serve as
a biomarker in an RA-ILD screening model to identify patients in need of further testing.
Pairing anti-MAA antibody with other serum biomarkers may further improve the
sensitivity and specificity for detecting RA-ILD and such work is underway. A proposed
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model for the enhanced identification of RA-ILD through a two-stage process
incorporating serum biomarkers is shown in Figure 8. In this proposed model,
individuals with RA are screened for RA-ILD with a panel of serum biomarkers that
includes anti-MAA antibody and that encompass the different pathophysiologic pathways
implicated in RA-ILD (autoimmunity, inflammation, fibrosis, and oxidative stress). Those
with a normal screening biomarker are then followed expectantly or with serial biomarker
testing, while an abnormal screening biomarker panel prompts further testing with a
high-resolution CT scan and PFTs. If RA-ILD is confirmed, then patients are referred for
management of ILD, ideally in a multi-specialty treatment center. Patients with
indeterminate test results (e.g. abnormal serum biomarkers with equivocal CT/PFT
findings) or normal test results are considered high-risk, monitored serially, and targeted
with preventive strategies (e.g. smoking cessation or avoidance of other airway irritants).
This screening and confirmation approach to the identification is in contrast to a
universal testing approach where all patients with RA undergo high-resolution CT
scanning and PFTs. This would maximize the sensitivity for detecting RA-associated
lung diseases, provide prognostic information when lung disease is present, and could
identify other lung pathologies like lung cancer, which is increased approximately 60% in
RA patients.140 However, universal CT and PFT testing would be an expensive
approach, adding to the economic burden of RA on the health care system which
already imposes a total annual cost of over $19 billion dollars.141 This also imposes
significant costs to patients, who have greatly benefited from the efficacy of bDMARDs
but also economically impacted by their costs.142 Other limitations of the universal testing
approach include exposing RA patients to unnecessary radiation and the detection of
incidental findings, a phenomenon that leads to additional medical testing, medical
costs, unnecessary procedures, and anxiety for patients.143
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Which biomarkers to include in the proposed RA-ILD screening model is an area
for future study. Candidate biomarkers evaluated to date in RA-ILD and their
performance are listed in Table 17. Many of these biomarkers have also been studied in
other connective tissue disease related ILD or IPF.144-147 Since the primary use of these
biomarkers will be screening for ILD in a RA cohort, this lack of specificity for the
systemic disease causing the ILD is of little consequence. Most of these RA-ILD
biomarkers have been tested in isolation, with the exception of the combination of MMP7, PARC, and SP-D studied by Doyle et al.72 Future studies should test whether other
combinations of these and other newly identified RA-ILD biomarkers have value in
combination to further develop and refine this ILD screening model. Because of the
potential for multicollinearity between serum biomarkers, analytic techniques such as
principal component analysis should be considered in future efforts to identify biomarker
signatures.148 Although serum and sputum/bronchoalveolar biomarkers have been
investigated in RA-ILD,149 serum biomarkers are greatly preferred because of the added
feasibility of collecting the samples.
Additional questions arise from this proposed RA-ILD screening model. When
and how often should ILD screening biomarkers be tested? Immediately at the time of
RA diagnosis or later in the disease course? RA-ILD is often thought to be a feature of
established RA. Supporting this, Kelly et al. found the median duration of RA at ILD
diagnosis was 9 years.48 However, other studies have highlighted the early appearance
of ILD in RA patients. Koduri et al. reported that over 50% of ILD cases occurred within 3
years of RA diagnosis.47 In a small cohort of 37 subjects with RA for <2 years, Gabbay et
al. detected evidence of ILD on CT in 58% of subjects.65 Finally, ILD may even present
before RA in approximately 10-15% of cases.47,48 Other pulmonary abnormalities,
including involvement of the airways, may also predate the appearance of RA.51 Based

85

on these results, we propose that the initial ILD screening should occur early after RA
diagnosis. This timing would be further justified if these candidate biomarkers are
demonstrated to be predictive of incident ILD. Whether anti-MAA antibody, as well as
other candidate RA-ILD biomarkers, can predict the incidence or progression of ILD or
prognosticate survival are areas of planned investigation.
The RA-ILD screening protocol proposed is intended for the identification of ILD
in previously diagnosed RA patients. When the ILD predates articular symptoms, there is
a need for a diagnostic evaluation of unspecified ILD to establish a diagnosis of RA. In
this situation, it is expected that established RA autoantibodies, RF and ACPAs, will be
more helpful than the ILD biomarkers listed in Table 17. With a specificity of >95%,119
the presence of ACPAs would be highly suggestive of RA as the underlying connective
tissue disease. Although ACPAs and RF may be absent in up to 30-40% of RA patients,
the sensitivity for RA is likely to be greater in the setting of this extraarticular
manifestation because these antibodies are strongly associated with the presence of
RA-ILD.48,66,71,72 In contrast, the specificity of ACPAs and RF may be lower in this setting
because other chronic lung diseases are associated with the presence of ACPAs in the
absence of RA.49 These hypotheses on the diagnostic performance of ACPAs and RF
for RA in the setting of ILD warrant future investigation.
While the association of serum anti-MAA antibody with RA-ILD in Chapter 3
support its integration into future RA-ILD screening efforts, the enhanced staining for
MAA modified proteins in the lungs from RA-ILD subjects and co-localization with other
autoantigens, immune effector cells, and extracellular matrix proteins also implicates this
post-translational modification in the pathogenesis of RA-ILD. Animal and in vitro studies
building upon these findings could begin to elucidate the mechanisms by which MAA
modification and the immune responses targeting MAA-modified proteins may facilitate
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the loss of tolerance to citrullinated antigens and drive pro-inflammatory and/or profibrotic responses within the lungs. For example, differentiation of fibroblasts into
activated myofibroblasts as a result of epithelial injury and inflammatory responses is a
central process in the development of pulmonary fibrosis.150 MAA could serve as a proinflammatory mediator between oxidative stress related epithelial injury and activation of
myofibroblasts in RA-ILD. In IPF, anti-oxidant therapies (N-acetylcysteine) have been
tested in several randomized controlled trials with mixed results.151-153 Further evaluation
of the role of MAA in this pathway may elucidate novel targets for RA-ILD therapies.
Moreover, to date, anti-MAA antibodies have been detected using MAA modified
albumin, which is not a relevant antigen in the pathogenesis of RA and RA-ILD. AntiMAA antibodies targeting relevant RA and RA-ILD antigens may have better specificity
for disease detection as well as further our understanding of the role of MAA
modification in RA and RA-ILD pathogenesis.
The development of administrative algorithms that can accurately classify RA-ILD
in Chapter 4 provides for the first time a tool that can be readily implemented in large,
real-world datasets to enhance the identification of RA-associated lung disease.
Recognizing that we tested our algorithms in a cohort of RA subjects who had definitive
RA meeting formal disease classification criteria, the application of these algorithms in
datasets where RA case identification is conducted solely with administrative data could
impact their performance. To better understand this potential threat to external validity,
we are currently collaborating on an effort to test these algorithms for ILD in combination
with administrative algorithms for RA in large non-VA data sources. Given the high
specificity of administrative algorithms for RA80 and the vast overrepresentation of ILD in
RA,57 we expect similar ILD algorithm performance in combination with administrative
algorithms for RA.
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The algorithms developed in Chapter 4 used data that is nearly universally
available in administrative claims. Because the adoption of electronic medical records
has become widespread,154 leveraging the additional data available in electronic health
records to improve these algorithms represents an exciting and rapidly emerging
opportunity. Electronic medical records not only contain the orders for diagnostic testing
and billing diagnoses, but have diagnostic testing results and clinical notes containing
provider assessments, diagnoses, and management plans. Tools such as natural
language processing could be used to build on these administrative algorithms by
facilitating the development of electronic medical record computable phenotypes.155
Leveraging state-of-the-art text mining approaches, characteristic imaging findings such
as “reticular opacities”, “ground glass”, “honeycombing”, and “fibrosis” could be searched
for, as could RA-ILD patterns including “usual interstitial pneumonia” and “non-specific
interstitial pneumonia”. PFT results could be incorporated using a similar approach,
allowing for identification of reductions in forced vital capacity or diffusion capacity that
result from RA-ILD.138 While the potential availability of such robust data sources is
exciting, the methods by which these different data components are stored and
accessed varies between health care systems and electronic medical record vendors.
Thus, widespread adoption of these algorithms will likely pose an ongoing challenging
until interoperability between health care systems and vendors is achieved.156
While better disease activity, functional status, and a reduced need for joint
replacement surgeries have resulted from RA treatment advances,36-38 it is uncertain if
the incidence of RA-associated lung disease has declined. Cohorts constructed from
these algorithms could address this question, as well as investigate determinants and
trends of survival in RA-ILD. These prevailing research questions illustrate the potential
near-term uses of these algorithms for epidemiologic and outcomes research. Other
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uses for these algorithms include clinical trial planning and enrollment. Deploying these
algorithms will assist with determining if an adequate number of subjects exist to support
a clinical trial and then to facilitate clinical trial recruitment. A similar model was
successfully implemented to recruit for a large pragmatic trial of aspirin for the
prevention of cardiovascular events.157
The algorithms developed in this dissertation focused on RA-ILD, given that RAILD is the most fatal RA-associated lung disease. Deriving and validating other chronic
lung disease algorithms in RA is an area for future work. Administrative algorithms for
COPD have been developed in the general population through the use of multiple
diagnostic codes from outpatient or inpatient encounters,158 though they may not
appropriately distinguish COPD from other obstructive lung diseases, namely asthma.159
Algorithms using electronic health record data, which contains data elements not
available in administrative health databases, have also been proposed for COPD. The
addition of smoking status, COPD related medications, and other medical record data
elements (e.g., the past medical history and problem list) may improve algorithm
performance.160 Since the evaluation and management of COPD in RA does not differ
substantially from the general population, it is anticipated that these algorithms would
perform similarly in RA cohorts. Algorithms for other RA-related pulmonary
manifestations such as bronchiectasis, bronchiolitis, RA nodulosis (of the lungs), and RA
pleural effusions have not been studied in RA or more broadly the general population.
Results detailed in Chapter 4 illustrate that diagnostic codes pertaining to “rheumatoid
lung” are often used to designate these conditions. Therefore, use of this non-specific
ICD code will likely make it challenging to derive accurate algorithms for these conditions
using only administrative data.
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While this dissertation focused on the identification of RA-associated lung
disease, the poor prognosis observed in these individuals may relate, in part, to the fact
that optimal treatments for RA-associated lung disease are not known. To date, there
have been no completed randomized controlled trials of therapies in RA-associated lung
diseases or clinical guidelines for the management of RA-associated lung diseases.
Complicating therapy selection further, most RA therapies have been linked with druginduced pneumonitis, including methotrexate, leflunomide, sulfasalazine, TNFi,
rituximab, abatacept, and tocilizumab.74-76,161
Of the RA therapies linked with pneumonitis, this phenomenon has been most
widely described as a complication of methotrexate.162,163 Providers often avoid
methotrexate in RA-ILD patients,78 opting for alternative RA therapies that have also
been linked to pneumonitis or fatal ILD exacerbations.74 In a meta-analysis of 22
randomized controlled trials with 8,584 RA patients, methotrexate pneumonitis was
exceedingly rare, occurring in <0.3% of subjects.163 Moreover, the authors did not find
methotrexate to be associated with non-infectious respiratory events or respiratory
mortality. Findings detailed in Chapter 2 evaluating mortality in RA patients with and
without lung disease suggest that methotrexate should not be routinely avoided in RA
patients with chronic lung disease. Using several models with various analytic
approaches, methotrexate was either associated with a lower risk of mortality or not
significantly associated with mortality in those with lung disease. These analyses did not
study methotrexate in RA-ILD specifically since validated algorithms for classifying ILD
were not available at that time, a limitation that can now be addressed through our work
deriving RA-ILD algorithms (Chapter 4). Whether methotrexate leads to adverse
outcomes specifically in RA-ILD is an important knowledge gap and an area of planned
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study, given methotrexate treatment results in improvements in disease activity and
survival.164
Advanced RA therapies, such as bDMARDs, have led to substantial
improvements in RA outcomes, although data specific to patients with ILD is sparse. A
single, small, open-label uncontrolled study of rituximab in RA-ILD showed stability of
PFTs in completers, but two died over the course of a 48-week study.165 The remainder
of studies of RA therapies in RA-ILD have been observational and hampered by a
number of methodological limitations. Dixon et al. found numerically more ILD-related
deaths among RA-ILD subjects treated with TNFi compared to conventional DMARDs.115
In a later study from the same registry, rituximab treatment was associated with a lower
risk of mortality than TNFi in RA-ILD.166 These studies relied on a single questionnaire
response by the treating provider to establish the diagnosis of RA-ILD, an approach
prone to misclassification. Curtis et al. evaluated the risk of hospitalization for respiratory
events in RA-ILD using a large administrative data source, finding no significant
differences different between bDMARDs.77 The algorithms employed likely suffered from
poor specificity leading to misclassificatoin. As the selection of advanced RA therapies in
RA-ILD remains challenging, we have planned a study leveraging our RA-ILD algorithms
and large, real-world data sources to compare the effectiveness and safety of advanced
RA therapies in RA-ILD. Our proposed study uses a new-user, active-comparator design
to reduce confounding and selection bias.167 To further reduce confounding bias, we will
use inverse probability of treatment weighting to balance pre-specified covariates related
to the prognosis in RA-ILD between treatment groups.168
Anti-fibrotics have become standard of care for the treatment of IPF, slowing the
rate of progression and reducing mortality by 30-50%.169-171 Owing to the similarities of
RA-ILD to IPF, randomized controlled trials of anti-fibrotics (pirfenidone [NCT02808871]
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and nintedanib [NCT02999178]) in RA-ILD are currently enrolling. Recently, a
randomized controlled trial of nintedanib in systemic sclerosis-ILD was completed finding
less decline in PFTs with nintedanib compared to placebo.172 However, there was no
improvement in other systemic sclerosis or ILD outcomes (e.g., modified Rodnan skin
score and St. George’s Respiratory Questionnaire) and background mycophenolate
treatment appeared to be most influential on PFT progression. Extrapolating from this
study, it seems unlikely that anti-fibrotics will replace the need for DMARDs in RA. Other
lung focused therapies such as azathioprine, mycophenolate, cyclophosphamide, and
tacrolimus (agents that are not routinely used to treat articular disease in RA) have been
evaluated in small, uncontrolled studies that included RA-ILD.173-176 However, the precise
role of these therapies in RA-ILD is unclear. With the anticipated increased use of lung
targeted therapies in RA-ILD, pharmacoepidemiologic studies will be needed to assess
the efficacy and safety of these agents, particularly when used in combination with RA
DMARDs used to manage articular manifestations.
Optimal treatments in other RA-lung diseases are also unknown. There is
concern about the safety of using abatacept in RA patients with COPD based on an
increased frequency of COPD exacerbations reported in a single randomized controlled
trial of abatacept in RA.91 However, a recent pharmacoepidemiologic study with a
prevalent new-user design and time-conditional propensity score matching compared
abatacept to other bDMARDs in RA subjects with COPD found no increased risk of
respiratory events.177 Bronchiectasis, another form of chronic lung disease that can
complicate the course of RA, is characterized by bacterial colonization of the lower
respiratory tract that increases the risk of pulmonary infections.178 Treatment with
biologic therapies is worrisome in these patients because of the increased risk for
serious infection.179 Although not limited to bronchiectasis, findings detailed in Chapter 2
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reassuringly did not identify conventional or bDMARDs to be associated with a
significantly higher mortality risk in RA patients with chronic lung disease. Much more
pharmacoepidemiologic evaluation of RA therapies in those with chronic lung diseases
are needed, but development of valid algorithms for identifying these conditions (as we
have done for RA-ILD) will be an important first step to facilitate this line of investigation
moving forward.
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Figure 8. Incorporation of serum biomarkers into RA-ILD identification

Proposed model for the incorporation of serum biomarkers into the identification of
rheumatoid arthritis interstitial lung disease (RA-ILD). Multiple biomarkers are used to
screen RA cohorts for ILD or individuals at high-risk for ILD. Confirmatory testing is
obtained through a high-resolution computed tomography (HRCT), and pulmonary
function tests (PFTs) to establish the diagnosis, prognosis, and treatment plan.
Abbreviations: ACPAs, anti-citrullinated protein antibodies; HR, high risk; HRCT, highresolution computed tomography; ILD, interstitial lung disease; MAA, malondialdehydeacetaldehyde adducts; MMPs, matrix metalloproteinases; PFTs, pulmonary function
tests; RA, rheumatoid arthritis
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Table 17. Candidate serum biomarkers in RA-ILD
Biomarker

Description

Antibodies to
Anti-citrullinated protein
citrullinated
antibodies (ACPAs)
peptides/proteins

Anti-Cit-HSP90

Antibody targeting
citrullinated heat shock
protein 90, chaperone
proteins that regulate
protein folding

Anti-MAA antibody

Antibody to product of
oxidative stress

Anti-PAD3/4

Antibodies to PAD
enzyme isoforms 3 & 4

Interferon-γ-inducible
protein 10

Performance in RA-ILD
AUC 0.46-0.75 for discriminating RAILD from RA.71,72
Number of high level ACPAs
independently associated with ILD in
RA.66
High specificity (>95%) but low
sensitivity (<30%) for discriminating
RA-ILD from RA, mixed connective
tissue disease, and IPF.70
Higher quartiles of IgM antibody with
>2-fold higher odds of ILD in a large
RA cohort independent of traditional
RA-ILD risk factors. Higher values in
RA-ILD than RA with COPD.180
Presence of cross-reactive antibody
independently associated with 7-fold
higher odds of ILD in RA cohort181
AUC 0.71-0.74 for discriminating RAILD from RA.71

CXC family cytokine
involved in chemotaxis
Glycoprotein expressed
Krebs von den Lungenon pulmonary epithelial Correlates with ILD severity on CT.69
6
cells
Enzyme involved in the
Matrix
AUC 0.68-0.86 for discriminating RAremodeling of
ILD from RA.71,72
metalloproteinase-7
extracellular matrix
Pulmonary and
Chemotactic factor for
AUC 0.70-0.80 for discriminating RAT cells expressed in the
activation-regulated
ILD from RA.72
lungs
chemokine
Antibody targeting the
AUC 0.59-0.67 for discriminating RARheumatoid factor
Fc portion of an IgG
ILD from RA.71,72
Collectin secreted from
epithelial cells that
AUC 0.75-0.91 for discriminating RAprimarily mediates
Surfactant protein-D
ILD from RA.72
host-defense function
of surfactant
Abbreviations: AUC, area under the curve; Cit-HSP90, citrullinated heat shock protein
90; ILD, interstitial lung disease; IPF, idiopathic pulmonary fibrosis; MAA,
malondialdehyde-acetaldehyde adducts; PAD, peptidyl-arginine deiminase; RA,
rheumatoid arthritis
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5.3

Conclusion
RA-associated lung diseases are responsible for a significant proportion of the

morbidity and premature mortality in RA patients. Despite recognizing their existence for
over 60 years, there remains a poor understanding of their pathophysiology, optimal
methods for identification, and the best medications to select for treatment when
present. This dissertation advances our understanding of the impact that chronic lung
diseases have on mortality in RA patients, raising awareness and encouraging further
research to target pulmonary manifestations as aggressively as cardiovascular disease
has been targeted. To facilitate the earlier identification of RA-ILD, we identified a novel
autoantibody that is independently associated with RA-ILD that could be used as part of
a screening process for this extra-articular manifestation. Finally, we have developed
administrative algorithms that accurately classify RA-ILD status in RA cohorts that can
be used to leverage large, real-world datasets to perform high-impact comparative
effectiveness and outcomes research. Together, these studies improve our ability to
identify RA-associated lung diseases and the tools developed will facilitate the
completion of the proposed clinical and translational research in RA-associated lung
diseases.
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APPENDICES
APPENDIX A: Diagnostic Codes for Lung Disease Categories
Diagnostic codes corresponding to HCUP-CCS categories for lung diseases
HCUP-CCS category

ICD-9-CM codes

Included
127. Chronic obstructive pulmonary

490 4910 4911 4912 49120 49121

disease and bronchiectasis

49122 4918 4919 4920 4928 494 4940
4941 496

128. Asthma

49300 49301 49302 49310 49311 49312
49320 49321 49322 49381 49382 49390
49391 49392

132. Lung disease due to external agents

4950 4951 4952 4953 4954 4955 4956
4957 4958 4959 500 501 502 503 504
505 5060 5061 5062 5063 5064 5069
5071 5078 5080 5081 5082 5088 5089

133. Other lower respiratory disease

5131 514 515 5160 5161 5162 5163
51630 51631 51632 51633 51634 51635
51636 51637 5164 5165 51661 51662
51663 51664 51669 5168 5169 5172
5178 5183 5184 51889 5194 5198 5199
7825 78600 78601 78602 78603 78604
78605 78606 78607 78609 7862 7863
78630 78631 78639 7864 78652 7866
7867 7868 7869 7931 79311 79319
7942 V126 V1260 V1261
V1269 V426

Not included
122. Pneumonia

00322 0203 0204 0205 0212 0221 0310
0391 0521 0551 0730 0830 1124 1140
1144 1145 11505 11515 11595 1304
1363 4800 4801 4802 4803 4808 4809
481 4820 4821 4822 4823 48230 48231

126

48232 48239 4824 48240 48241 48242
48249 4828 48281 48282 48283 48284
48289 4829 483 4830 4831 4838 4841
4843 4845 4846 4847 4848 485 486
5130 5171
123. Influenza

4870 4871 4878 488 4880 48801 48802
48809 4881 48811 48812 48819 48881
48882 48889

125. Acute bronchitis

4660 4661 46611 46619

126. Other upper respiratory infections

0320 0321 0322 0323 0340 460 4610
4611 4612 4613 4618 4619 462 4640
46400 46401 46410 46411 46420 46421
46430 46431 4644 46450 46451 4650
4658 4659 4730 4731 4732 4733 4738
4739 78491

129. Aspiration pneumonitis; food/vomitus

5070

130. Pleurisy; pneumothorax; pulmonary

5100 5109 5110 5111 5118 51189 5119

collapse

5120 5128 51281 51282 51283 51284
51289 5180 5181 5182

131. Respiratory failure; insufficiency;

5173 5185 51851 51852 51853 51881

arrest

51882 51883 51884 7991 V461 V4611
V4612 V4613 V4614 V462

HCUP-CCS: Healthcare Cost and Utilization Project Clinical Classification Software:
https://www.hcup-us.ahrq.gov/toolssoftware/ccs/ccs.jsp
ICD-9-CM: International Classification of Disease, 9th edition, Clinical Modification
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APPENDIX B: Diagnostic Codes for Cardiovascular Categories
Diagnostic codes corresponding to HCUP-CCS categories for cardiovascular disease
HCUP-CCS category

ICD-9-CM codes

96. Heart valve disorders

3940 3941 3942 3949 3950 3951 3952
3959 3960 3961 3962 3963 3968 3969
3970 3971 3979 4240 4241 4242 4243
42490 42491 42499 7852 7853 V422
V433

97. Peri-, endo-, and myocarditis;

03282 03640 03641 03642 03643 07420

cardiomyopathy

07421 07422 07423 11281 11503 11504
11513 11514 11593 11594 1303 3910
3911 3912 3918 3919 3920 393 3980
39890 39899 4200 42090 42091 42099
4210 4211 4219 4220 42290 42291
42292 42293 42299
4230 4231 4232 4233 4238 4239 4250
4251 42511 42518 4252 4253 4254
4257 4258 4259 4290

100. Acute myocardial infarction

4100 41000 41001 41002 4101 41010
41011 41012 4102 41020 41021 41022
4103 41030 41031 41032 4104 41040
41041 41042
4105 41050 41051 41052 4106 41060
41061 41062 4107 41070 41071 41072
4108 41080 41081 41082 4109 41090
41091 41092

101. Coronary atherosclerosis and other

4110 4111 4118 41181 41189 412 4130

heart disease

4131 4139 4140 41400 41401 41406
4142 4143 4144 4148 4149 V4581
V4582

105. Conduction disorders

4260 42610 42611 42612 42613 4262
4263 4264 42650 42651 42652 42653
42654 4266 4267 42681 42682 42689

128

4269 V450 V4500 V4501 V4502 V4509
V533 V5331 V5332 V5339
106. Cardiac dysrhythmias

4270 4271 4272 42731 42732 42760
42761 42769 42781 42789 4279 7850
7851

107. Cardiac arrest and ventricular

42741 42742 4275

fibrillation
108. Congestive heart failure, non-

39891 4280 4281 42820 42821 42822

hypertensive

42823 42830 42831 42832 42833 42840
42841 42842 42843 4289

109. Acute cerebrovascular disease

34660 34661 34662 34663 430 431
4320 4321 4329 43301 43311 43321
43331 43381 43391 4340 43400 43401
4341 43410 43411 4349 43490 43491
436

110. Occlusion or stenosis of precerebral

4330 43300 4331 43310 4332 43320

arteries

4333 43330 4338 43380 4339 43390

112. Transient cerebral ischemia

4350 4351 4352 4353 4358 4359

113. Late effects of cerebrovascular

438 4380 43810 43811 43812 43813

disease

43814 43819 43820 43821 43822 43830
43831 43832 43840 43841 43842 43850
43851 43852 43853 4386 4387 43881
43882 43883 43884 43885 43889 4389

114. Peripheral and visceral

4400 4401 4402 44020 44021 44022

atherosclerosis

44023 44029 4404 4408 4409 4439
5570 5571 5579

HCUP-CCS: Healthcare Cost and Utilization Project Clinical Classification Software (HCUPCCS): https://www.hcup-us.ahrq.gov/toolssoftware/ccs/ccs.jsp
ICD-9-CM: International Classification of Diseases, 9th edition, Clinical Modification
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APPENDIX C: Descriptions of “Other” Lung Codes
Descriptions of ICD-9-CM codes included in other lower respiratory disease (HCUPCCS category 133)
ICD-9-CM
513.1

Description
Abscess of the mediastinum

514

Pulmonary congestion

515

Post-inflammatory pulmonary fibrosis

516.0

Other alveolar and parietoalveolar pneumonopathy

516.1

Idiopathic pulmonary hemosiderosis

516.2

Pulmonary alveolar microlithiasis

516.3x

Idiopathic interstitial pneumonia

516.4

Lymphangioleiomyomatosis

516.5

Adult pulmonary Langerhans cell histiocytosis

516.6

Interstitial lung diseases of childhood

516.8

Other specified alveolar and parietoalveolar pneumonopathies

516.9

Unspecified alveolar and parietoalveolar pneumonopathy

517.2

Lung involvement in systemic sclerosis

517.8

Lung involvement in other diseases classified elsewhere

518.3

Pulmonary eosinophilia

518.4

Acute edema of lung, unspecified

518.89

Other diseases of lung, not elsewhere classified

519.4

Disorders of the diaphragm

519.8

Other diseases of respiratory system, not elsewhere classified

519.9

Unspecified disease of respiratory system

782.5

Cyanosis

786

Symptoms involving respiratory system and other chest
symptoms

793.1

Nonspecific findings on radiological and other examination of
lung field

794.2

Nonspecific abnormal results of pulmonary function study

V12.6

Personal history of diseases of respiratory system

V42.6

Lung transplant status

HCUP-CCS: Healthcare Cost and Utilization Project Clinical Classification Software
ICD-9-CM: International Classification of Diseases, 9th edition, Clinical Modification
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APPENDIX D: Diagnostic Codes for Interstitial Lung Disease
Diagnostic codes used for interstitial lung disease algorithms
Codes

Description

ICD-9
515

Postinflammatory pulmonary fibrosis

516.3x (516.30-516.37)

Idiopathic interstitial pneumonia

516.8

Other specified alveolar and parietoalveolar
pneumonopathies

516.9

Unspecified alveolar and parietoalveolar pneumonopathy

714.81

Rheumatoid lung

ICD-10
M05.1x (M05.10-M05.19)

Rheumatoid lung disease with rheumatoid arthritis

J84.1x (J84.10-J84.17)

Other interstitial pulmonary diseases with fibrosis

J84.2

Lymphoid interstitial pneumonia

J84.89

Other specified interstitial pulmonary diseases

J84.9

Interstitial pulmonary disease, unspecified

J99

Respiratory disorders in diseases classified elsewhere

Abbreviations: ICD, International Classification of Diseases
Bolded are recommended for future use based on study results.
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APPENDIX E: Procedure Codes for Interstitial Lung Disease
Procedure codes used in interstitial lung disease algorithms.
ICD-9-CM
Procedure
CPT
Procedure
Lung biopsy
Surgical

32095-32097, 32602,
32607-32608

33.20, 33.28, 34.21

Transbronchial

31628, 31629, 31632

33.27

Percutaneous

32405

33.26

Chest computed tomography (CT)
Chest CT
71250, 71260, 71270
Low dose CT chest
G0297
CT-angiogram
71275
Pulmonary function testsb
Spirometry
Lung volume
Diffusion capacity

94010, 94060, 94070,
94150, 94200, 94375
94250, 94726-94727
94729

ICD-10-PCSa
0BB30*X0BB90*X,
0BBB0*X0BBM0*X
0BB38*X0BB98*X
0BBB8*X0BBM8*X
0BB33*X0BB93*X
0BBB3*X0BBM3*X

87.41

BB24***

89.37, 89.38

4A09***

* Denotes any code in this position
additionally identified through pulmonary function test lab stop code (104)
Abbreviations: CPT, current procedural terminology; ICD-9-CM, International Classification of Diseases,
9th revision, Clinical Modification; ICD-10-PCS, International Classification of Diseases, 10th revision,
Procedure Coding System
a

b PFTs
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APPENDIX F: Diagnostic Codes for Other Interstitial Lung Disease
Diagnostic codes for other causes of interstitial lung disease.
Condition

ICD-9-CM

ICD-10-CM

135.x

D86.x

Systemic sclerosis

517.2, 710.1

M34.x

Myositis

710.3-710.4

M33.x

Systemic lupus erythematosus

710.0

M32.x

Hypersensitivity pneumonitis

495.x

J67.x

Pneumoconioses (including

500.x-505.x

J60.x-J64.x

508.1

J70.0-J70.1

Sarcoidosis

asbestos)
Radiation pneumonitis

Abbreviations: ICD, International Classification of Diseases; CM, Clinical Modification

